 
 
Revised Clinical Study Protocol 
Study Code PT010008 
NCT #  [STUDY_ID_REMOVED] 
Date 18 March 2016 
 
 
 
 
 
 
  
 
 
 
 
 A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-D osing, Multi-Center 
Study to Assess the Safety and Tolerability of PT010, PT009 and P T003 in Subjects with 
Moderate to Very Severe Chronic Obstructive Pulmonary Disease  
 
 
 
This submission /document contains trade secrets and confidenti al commercial information, disclosure of which 
is prohibited without providing advance notice to AstraZeneca a nd opportunity to object.  
The following Amendment(s) are included in this revised protoco l: 
  
Amendment No.        Date of Amendment                
Version 1 13 July 2015 
Version 2, Amendment 1 18 March 2016 
 
 
 

Clinical Trial Protocol: PT010008-01
Study Title: A Randomized, Double-Blind, Par allel-Group, 52-Week, Chronic-
Dosing, Multi-Center Study to A ssess the Safety and Tolerabilit y of 
PT010, PT009 and PT003 in Subjects w ith Moderate to Very Severe  
Chronic Obstructive Pulmonary Disease
Study Number: PT010008-01
Study Phase: III
Product Name: Budesonide, Glycopyrronium, and For moterol Fumarate Inhalation 
Aerosol, PT010
Glycopyrronium and Formoterol F umarate Inhalation Aerosol, PT003
Budesonide and Formoterol Fuma rate Inhalation Aerosol, PT009
EudraCT Number: 2014-005672-29
Indication: COPD
Investigators: Multicenter
Sponsor: Pearl Therapeutics, Inc.
200 Cardinal Way, 2ndFloor
Redwood City, CA 94063
1-650-305-2600
Sponsor Contact: Paul M. Dorinsky MD 
Version Number Date:  
Original Protocol Version 1.0 13 July 2015
Amended Protocol Version 2.0 18 March 2016
Confidentiality Statement
Property of Pearl Therapeutics
This document is confidential and may not be used, divulged, pub lished or otherwise 
disclosed without consent of  Pearl Therapeutics Inc.
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
SUMMARY OF CHANGES TO ORIGINAL PROTOCOL VERSION 1.0, 
DATED 
The amended study protocol, P T010008-01(Version 2.0), includes the following edits: 
Newly added text is shown in bold font  and deleted text is shown a s strikethrough font. 
No. Description of Change Rationale
1 Section 3 : Study Endpoints:  
All assessments are r elative to baseline 
assessments performed during the Study PT010006 Screening Period (between Visit 1 and Visit 3 4) To clarify Screening Period is 
considered between Visit 1 and Visit 4 and not between Visit 1 and Visit 3 in this section and throughout the document for consistency 
2 Section 4.1  Overall Study Design and Plan
Baseline and demographic characteristics 
collected in Study PT010006 will be used for subjects participating in this study. Baseline assessments ( BMD, lenticular 
opacity, fundoscopic examination, intraocular pressure , pupil dilation,  and 
visual acuity assessments) will be performed prior to randomization in 
Study PT010006. If the  first two BMD 
scans differ by m ore than 5% (as 
determined by the l ocal facility) for 
either site (i.e. first  two hip or first two 
lumbar sites) a third scan should be 
obtained .The screening period may be 
extended up to a maximum of 21 days if 
additional time is n eeded to complete the 
assessments during Study PT010006 
Screening Period (between Visit 1 and 
Visit 4). A separate informed consent will 
be obtained for subjects participating in 
Study PT010008 prior to any study 
PT010008 procedures .start of Study 
PT010006.
Subjects participating in Study PT010008 
who complete visit 10a of Study PT010006 will transition to the remaining 28 weeks of To clarify how the s can information will 
be analyzed, to allow adequate time to 
complete assessments during the screening period, and to ensure consistency across study section and sites
Removed a sentence about reference to 
revisions to SAP or D MC as this is not 
relevant to this section
Confidential and Proprietary Page 2 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
treatment by completing Visit 10b
(Week 24). Post-base line lenticular 
opacity, fundoscopic examination, intraocular pressure, and visual acuity assessments w ill be performed prior to at
Visit 11 (Week 28), and at Visit 14 (Week 
52)and Treatment
Discontinuation/Withdrawal Visit. A
post-baseline BMD a ssessment will be
performed prior to Visit 14 (Week 52)
and Treatment
Discontinuation/Withdrawal Visit .
Subjects will return to the clinic at Visit 12(Week 36), and Visit 13 (Week 44) toreturn used medication and obtain new
study drug. Subjects will return to theclinic at Visit 14 ( Week 52) to complete
final study visit procedures
Removed the following sentence: Further 
details will be provided in the DMC 
charter and in the Statistical Analysis Plan 
(SAP
3  Section 5.2.  Exclusion Criteria 
Subjects who meet any of the following 
criteria will be excluded from the study(please see the exception noted below theophthalmologic criteria Section 5.2.2 ).
Section 5.2.1  Bone Mineral Density 
Criteria applied to either hip or lumbar
region
1. Severe osteoarthritis osteoporosis
2. T-score < -2.5 at baseline
3. Added : Subjects unable to achieve an
acceptable scan (e.g. due to the
patientâ€™s inability to be stable duringthe procedure, due  to limitation of
scanning equipment to accommodatea subject ( ~300lbs or ~136kgs) or
other characteristics) .Added reference to exclusion criteria 
exception note (at end of Section 5.2.2 ) 
for allowance of subjects who meet none of the BMD exclusi on criteria but one or 
more of ophthalmologic exclusion criteria to continue  in the study based on 
the specified conditions 
Bone Mineral Density exclusion criteria  
clarified to indicate that it applied to either the lumbar or  the hip region and 
the following criteria were revised:  
1. severe osteoarthritis term is
corrected to reflect appropriate term"osteoporosis"
2. T-Score revised from a value of
"2.5" to  minus 2.5 "-2.5" to reflectthe excluded value and clarifiedeligibility when >1 scan was
Confidential and Proprietary Page 3 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
required
3. Added exclusion criteria to account 
for limitations of the scanning equipment  
4 Section 5.2.2 Exclusion Criteria
Ophthalmologic Criteria applied to either 
eye  
1. IOP >21mmHg  (lowest of the 3 
readings)
2. Note: Subjects with IOP >21mmHg 
may be treated and re-tested during the 
screening period. If the re-test 
measurements for IOP < 21mmHg 
this subject may be eligible
NOTE: Subjects who meet none of the 
bone mineral density exclusion criteria but who meet one or more
ophthalmologic exclusion criteria may be permitted to continue in the study. Such subjects woul d undergo all study 
planned assessments e xcept they would 
undergo no further ophthalmologic exams (all tests included in Section 7.2)  
during the randomized treatment period. Additionally such subjects would be permitted to continue in the study provided that the fo llowing 2 conditions 
are satisfied:
â€¢,23LVÂ”PP+JHLWKHUZLWKRU
without treatment  
â€¢In the opinion of the optometrist/opht halmologist, the 
subject does not have a condition (e.g., advanced glauco ma) that the 
eye health of the  subject could be 
jeopardized b y continued 
participation in the study
 Ophthalmologic exclusion criteria:            clarified to indicate that this criteria 
applies to either eye and the following are revised: 
1. The lowest of the 3 IOP readings 
should be considered to evaluate the exclusion of IOP >21mmHg  
2. Note is revised t o indicate what re-
test value of the  IOP could qualify 
subjectâ€™s eligibility 
Added exclusion criteria exception note 
(at end of  Section 5.2.2 ) for allowance 
of subjects who meet none of the BMD exclusion criteria  but one or more of 
ophthalmologic exclusion criteria to continue in the study based on the specified conditions 
5 Section 5.4.2 Prohibited COPD To continue  alignment with Study 
PT010006 at the start of this 
Confidential and Proprietary Page 4 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Medications
1. Table (Table 5-1) . ICS was deleted 
2. Theophylline details were revised to 
indicate Theophylline (<400 mg/day) is 
permitted provided the subject has 
been on a stable dose of therapy for at least 4 weeks prior to randomization in Study PT010006
3.Note below this table
Subjects who are ste roid dependent and 
maintained on an e quivalent of up to 5 
PJRUDOSUHGQLVRQHSHUGD\RUÂ”PJoral prednisone every other day are permitted to enroll in the study provided they have been on a dose of oral steroids that remains consistent 
and does not exceed this threshold 
for the last two weeks prior to randomization (Visit 4) in Study PT010006supplemental study
6 Section 5.4.3  Other Prohibited 
Medications 
Inserted Table 5.3 Non-COPD 
Medications Allowed Under Certain ConditionsTable 5.3 added to align with Study
PT010006 at the start of this supplemental study 
7 Section 5.4.3 Other Prohibited Medications 
Table 5.4   
1. Wording before  Table 5.4 revised
Subjects requiring medications presented in Table 5.4 are prohibited from 
participating in this study. Subjects who 
recently discontinued use of these 
medications may be considered for study enrollment provided t hey have met the 
minimum Washout Period prior to Visit 1 in Study PT010006.
These medications are prohibited 
throughout the cours e of the study, and, 
should a subject require  use of any of the 
listed medications , they should be To continue alignment with Study 
PT010006 at the start of this supplemental study  
1. Wording prior to Table 5.4 revised 
to allow Investigator judgement  
2. Table 5.4 added exception of 
carvedilol To align with exclusion criteria for CHF Class I and II treatment as these subjects are permitted to par ticipate in the study
3. Table 5.4 footnote revised  and 
description added to align with Study PT010006 
4.Table 5.4 footnote revised  and 
description added to align with Study PT010006 and allow 
Confidential and Proprietary Page 5 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
discontinued the investigator should 
evaluate the appropriateness of 
continuing the subject in the study
2.Table 5.4 revised to add exception of 
carvedilol for non-specific beta 
blocking agent
3.Table 5.4 Footnote added: 
Anticonvulsants for seizure or other 
indications allowed  provided the patient was treated with this class of medications during  Study PT010006
4.Table 5.4 Footnote revised:  
Antipsychotic agents and tricyclic 
antidepressants us ed for previously 
diagnosed underlying m edical conditions
are allowed  after consultation with the 
Peral Medical Monitor if, in the opinion of 
the Investigator, the re are no concerns 
regarding patient s afety, and if the 
patient has been on a stable dose for at 
least 6 weeks .Investigator opinion in the treatment 
of the study subject 
8 Section 7.1 Bone Mineral Density 
Assessments 
Bone mineral density will be evaluated by 
taking two sets of DEXA scans (lumbar 
spine and hip regions) prior to 
randomization (Study PT010006 Visit 4
) within 14 days prior to baseline 
(Screening Visits 1 to 4 in Study 
PT010006) and within 14 days prior to and 
Visit 14 (Week 52) in this study . After the 
first scan, of the lumbar spine and hip 
region, the subject will get up from the 
table, and be repositioned, and another 
scan taken to take anot her set of scans at 
these skeletal sites . If these first two scans 
differ by more than 5%  (as determined by 
the local facility) for either site (i.e. first 
two hip or first two lumbar sites)   a third 
scan should be obtained. The screening 
period may be extended up to a To clarify how the  scan information 
will be analyzed, allow adequate time to complete assessments during the screening period and to ensure consistency across study sites
Confidential and Proprietary Page 6 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
maximum of 21 days if additional time is 
needed to complete the assessments. The 
results of these scans w ill be provided by 
the central testin g facility to the 
investigative site t o allow appropriate 
management of the subject
If a subjectâ€™s T score is < 2.5 For any 
clinically relevant reduction in T-score ,
the investigator should consider appropriate tr eatment options based on 
local guidelines  for the subject and/or refer 
them to their local medical doctor or a specialist for treatment. If subsequently 
treated with bisphosphonates, the subject 
should be excluded from further BMD 
measures in this study If a subjectâ€™s T-
score (hip or lumba r spine) is <-2.5 at 
screening they are excluded . 
Both the lumbar spine L2-L4 and total hip 
bone density will be measured. The 2scans 
of each skeletal site will be centrally 
analyzed and averaged  to obtain the final 
result to be used for data analysis . The 
results of these scans w ill be relayed by the 
local facility to the investigator to allow 
appropriate management of the subject
Full details can be found in the BMD 
manual
9 Section 7.2 Ophthalmologic Assessments
1. The baseline ophthalmologic 
assessment must be performed prior to 
randomization  between Visits 1 and 4 
(Screening) of Study PT010006. Two 
post-baseline ophthalmologic assessments will be pe rformed at Visit 
11 (Week 28), and within 14 days 
prior to  Visit 14 (Week 52) only per 
exclusion criteria exception noted in 
Section 5.2.2 . These post-baseline 
ophthalmologic assessments should be scheduled to occur within two weeks For #1, Added consistency with respect 
to baseline assessment being conducted prior to randomization and within 14 days and concept for Visit 14 removed to correct an error for this study. For the two post-baselin e ophthalmic 
assessments added clarification to refer to the exclusion criteria exception noted 
in Section 5.2.2
For #2 and # 3, Included pupil dilation 
and clarified that a certified LOCSIII trained ophthalmologist /optometrist could conduct assessments 
Confidential and Proprietary Page 7 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
prior to the scheduled clinic visit. Due 
to diurnal variability of IOP, all ophthalmic examinations  following the 
first ophthalmic examination (screening  baseline) should be 
scheduled to occur within two hours of 
the time of day when the baseline ophthalmic examination was performed. The same ophthalmologist should perform the ophthalmic examinations for a g iven subject at all 
visits if possible, to e nsure consistency.  
2. At participating centers, all subjects 
will be referred to a precertified 
LOCSIII trained 
ophthalmologist/optometrist for 
evaluation of pupil dilation , lenticular 
opacities, fundoscopic examination, intraocular pressure (IOP), manifest refraction and visual acuity. This data will also be categorized as normal/abnormal.  
3. The Lens Opacities Classification 
System (LOCS) III grading system will be used to assess lenticular opacities in this study. The following assessments will be performed usin g a decimalized 
scale ranging from 0.1 (indicating acompletely clear or c olorless lens) to 
either 5.9 (indicating complete opacification on the cortex or posterior capsule for C or P scales) or 6.9 (indicating advanced opacification and brunescence of the nucleus for NO or NC scales). Each assessment will be recorded to the nearest 0.1 as determined by the certified
ophthalmologist/ optometrist . 
4. Moved the â€œNOTE: The 
ophthalmologist/optometrist must not refer to prior LOCS III grades and LOGMAR visual acuities from For #4 The Note moved with the LOCS 
III assessment to add relevance For #5 Eligibility criteria clarified with respect to the reading to be considered.
Confidential and Proprietary Page 8 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
previous ophthalmic e xamination at the 
time of a new examinationâ€ with the LOCS III assessment 
5.The lowest reading will be 
considered to determine eligibility
10 Added: Section 7.3.5 : EXACT
The exacerbations of chronic pulmonary 
disease tool (EXACT) questionnaire will be captured via the s ubject eDiary (see 
Appendix 4)  To align and include as a eDiary 
assessment
11 Section 7.6.1 : Medical/Surgical History 
and Physical Examination.
Weight, assessed in ordinary indoor 
clothing with shoes removed will be recorded at Visit 1 (Screening) (PT010006 
Screening)  and Visit 10a only. Height will 
be recorded at Visit 
1(Screening) (PT010006 Screening)
only. To reference back and align screening
procedures with Study PT010006 
12 Synopsis and  Section 7.7.13 Clinical 
Endpoint Committee 
Updated to change the adjudication 
committee name to Clinical Endpoint Committee and define their responsibilitiesTo clarify that there is one committee 
for adjudication which is also known as Clinical Endpoint Com mittee and there 
are three Clinical  Endpoint Adjudication 
Charters.
13 Synopsis and Section 7.7.14 Data 
Monitoring Committee
The responsibility was updated to 
include assessment of all safety data  To provide clarity that the DMC 
provides assessment  of all safety data 
not just SAEs. 
14 Table 8.1 Revised to move a footnote 
under footnote â€œaâ€ from footnote â€œgâ€ and revise section referenced to the correct section in this Note:
a.Scheduling visits :All visits will be scheduled relative to Visit 
10a (Week 24) of the lead-in study (PT010006).
Note: Refer  to Section 8.68 for procedures that may be required at a 
premature discontinuation visit. Treatment 
Discontinuation/Withdrawal Visits will be captured as unschedul ed Table 8.1 : Revised the placement of the 
note to provide relevance and corrected section to reference to Section 8.8 
appropriately 
Confidential and Proprietary Page 9 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
visits
Added Section 8.1  Baseline Assessments .  
1.The Baseline PT010008 Assessments 
will be conducted concurrently with 
PT010006 Screening.  All study assessments are to be completed prior to Randomization (Visit 4) in PT010006. 
â€¢Obtain informed consent prior to 
conducting any Study PT010008 
baseline assessments.
â€¢Register subject in IWRS for Study 
PT010008 at the same time 
registering in Study PT010006.  
â€¢Conduct BMD assessments (Refer to 
Section 7.1 ) 
â€¢Conduct ocular assessments (Refer 
to Section 7.2 ) 
2.Randomization 
â€¢Review Study PT010008 
inclusion/exclusion criteria and 
confirm subjectâ€™s eligibility to continue.
â€¢Obtain subject randomization 
number and treatment assignment 
information from IWRS.   
Note :  Randomization in PT01008 occurs simultaneously with randomization in Study PT010006 for those patients who qualify for Study PT010008. 
â€¢A reminder phone contact should be made prior to Visit 10b. Section 8.1 :To add the deta ils of the: 
1. Baseline procedures for this 
supplemental study to connect to the Study PT010006 where these subjects were screened
2. Randomization procedures in 
alignment with the schedule of events Table 8.1 
15 Section 8.3 Visit 10b
1. There are 10 scheduled visits in Study 
PT010006; the tenth visit is The last 
visit of the Study PT010006 and the 1. and bullet 3: To clarify BMD/ocular 
study as PT010008 and align with schedule of events
Confidential and Proprietary Page 10 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
first post-baselin e visit of the 
supplemental Study (PT010008).  In 
order to differentiate, assessments 
conducted at the co mpletion of the 
supplemental study PT010008, all 
baseline bone mineral density (Section 
7.1) and ocular (Section 7.2)
assessments will be captured during 
Screening (Visits 1 to 4) of Study 
PT010006.  Visit 10b will 
be completed follo wing completion of 
all Visit 10a study procedures. A
reminder phone contact should be made 
prior to Visit 10b  
2. Review BMD/Ocular sub study
inclusion/exclusion criteria
3. Register subject in IWRS to confirm 
participation in the  BMD/Ocular sub
study PT010008 and receive assigned 
treatment
4. Subject will administer dose of study 
drug at home in the evening Note: During the sub study subjects 
will continue on the  same treatment 
that they were assigned in Study PT010006 
5. Schedule ophthalmolo gic assessment to 
occur within two weeks prior to Visit 
11 (Week 28) 2. and bullet 4: Clarified "Note" to 
remove "sub" study 
5. Removed â€within two weeksâ€ for 
consistency throughout as not required
16 Section 8.4 Visits 11 (Week 28)
â€¢Confirm scheduled oc ular assessments 
have been conducted (Visit 11 should 
be rescheduled if ocular assessments not conducted prior to this visit)  
Please refer to the exclusion criteria 
exception noted in Section 5.2.2  to 
see if the ocular asse ssment applies to 
this visit . Added reference to the exclusion criteria 
exception noted in Section 5.2.2  to 
conduct ocular assessment for this visit only if applicable 
17 Section 8.7  Visit 14 (Week 52; Final Visit)
â€¢Confirm ocular assessments were 
conducted prior to this visit (Visit 14 Added reference to the exclusion criteria 
exception noted in Section 5.2.2 to 
conduct ocular assessment for this visit 
Confidential and Proprietary Page 11 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
should be rescheduled if ocular 
assessments not conducted prior to this visit) Please refer to the 
exclusion criteria exception noted 
in Section 5.2.2 to see if the ocular 
assessment applies to this visitonly if applicable
18 Section 9.1 : Introduction revised sentence 
as follows: 
This is a supplemental study to 
Study PT010006 PT010008 and will be 
conducted in a subs et of US sites 
participating in Study PT010006, and will 
evaluate the following treatmentsRevised to clarify language and 
reference to appropriate studies (PT010006 and PT010008) 
19 Section 9.4.1.1 Percent change from 
baseline in BMD of the lumbar spine measured using DEXA scans of L2-L4 
T- and Z- scores will be presented as 
shifts from baseline to each time point; details will be pr ovided in the SAP.
Section 9.4.1.2  Percent change from 
baseline in total hip BMD of the hip measured using DEXA scans 
The change from base line in BMD of the 
lumbar spine hip at Week 52 (and similarly at EoT) will be analyzed using 
an Analysis of Covariance (ANCOVA) 
model with treatme nt group and gender as 
categorical covariates and similarly to the 
change from baseline in BMD score, age, 
and age by gender interaction as 
continuous covariates of the lumbar 
spine.
T  and Z  scores will be  presented as shifts 
from baseline to eac h time point; details 
will be provided in the  SAP. Shift tables 
reported row percenta ges calculated using 
non missing row totals. Revised to place deta ils in appropriate 
sections
Confidential and Proprietary Page 12 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Study PT010006 will not be enrolled i n this supplemental study.   The entire study period is 
scheduled to take approximate ly 58 weeks for most subjects. 
An additional separate  informed consent w ill be obtained for su bjects participating in Study 
PT010006 who volunteer to participate in Study PT010008.  This study will evaluate the effects 
of BGF MDI, BFF MDI, and GFF MDI on BMD measurements and ocular  assessments. 
Baseline and demographic charact eristics collected in Study PT0 10006 will be used for subjects 
participating in this study. Bas eline BMD (Dual Energy X-ray Ab sorptiometry [DEXA] Scans) 
measurements and ocular assessme nts (Lens Opacities Classificat ion System [LOCS] III, 
fundoscopic examination, intraoc ular pressure, and visual acuit y) will be performed during Study 
PT010006 Screening Period (betw een Visit 1 and Visit 4).  
Subjects participating in PT 010008 who complete visit 10a of St udy PT010006 will transition to 
the remaining 28 weeks of treatme nt by completing Visit 10b (Wee k 24) of Study PT010008. 
Post-baseline lenticular opaci ty, fundoscopic examination, intr aocular pressure, and visual acuity 
assessments will be perfo rmed at Visit 11 (Week 28), at Visit 1 4 (Week 52), and/or at a 
Premature Discontinuation/Early Withdrawal Visit. A post-baseli ne BMD measurement will be 
performed at Visit 14 (Week 52) or  at a Premature Discontinuati on/Early Withdrawal Visit 
occurring after Visit 10b. Subject s will return to the clinic a t Visit 12 (Week 36) and Visit 13 
(Week 44) to return used and obtain ne w supplies of study drug.  Subjects will return to the clinic 
at Visit 14 (Week 52) to complete fi nal study visit procedures.  
A follow up telephone call will  be performed at least 14 days a fter last study drug. 
Study Population:
This study will include a subset  of approximately  500 randomize d subjects participating in Study 
PT010006 who were randomized to bli nded study treatment (BGF MD I, GFF MDI, and BFF 
MDI). Subjects will continue to receive the same treatment they  were randomized to receive in 
PT010006. 
Confidential and Proprietary Page 14 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Product, Dose, and Mo de of Administration:
Investigational materials will  be provided by Pearl Therapeutic s (Pearl), as shown below: 
Product Name & Dose Product StrengthDosage Form/
Fill CountAdministration
Study Medications
BGF MDI (PT010)
320/14.4/9.6 Î¼g ex-actuator160/7.2/4.8 Î¼g per actuation MDI/
120 inhalationsTaken as 
2 inhalations BID
GFF MDI (PT003)
14.4/9.6 Î¼g ex-actuator7.2/4.8 Î¼g per actuation MDI/
120 inhalationsTaken as 
2 inhalations BID
BFF MDI (PT009) 
320/9.6 Î¼g ex-actuator160/4.8 Î¼g per actuation MDI/
120 inhalationsTaken as 
2 inhalations BID
Open-Label Products
Albuterol Sulfate inhalation 
aerosol 90 ÈJa
ex-actuator US source: VentolinÂ®HFA
HFA inhalation aerosol will be the US-
supplied product.â€  Albuterol sulfate 
inhalation aerosol.  Each inhalation 
contains 108 ÈJFRUUHVSRQGLQJWR Î¼g 
albuterol base from the mouthpieceMDI/
60 or 200 actuationsTaken as directed
Supplies are open-
label 
BID=twice daily; BGF MDI=Budesonide, Glycopyrronium and Formote rol Fumarate Inhalation Aerosol; 
GFF MDI=Glycopyrronium and Formoterol Fumarate Inhalation Aeros ol; BFF MDI=Budesonide and Formoterol Fumarate 
Inhalation Aerosol; HFA=Hydrofluroalkane; MDI=Metered Dose Inha ler.
aRescue medication during the study.
All study drugs will be administered by oral inhalation.
Duration of Treatment: 
It is planned that each subject w ill receive study treatment fo r 52 weeks with the initial 24 weeks 
of exposure coincident with S tudy PT010006.  It is anticipated that the entire study will take 
approximately 58 weeks for each i ndividual subject from the tim e of Screening in Study 
PT010006. 
Bone Mineral Density Endpoints:
The primary BMD endpoint is: 
â€¢Percent change from baseline in B MD of the lumbar spine measure d using DEXA scans of 
L2-L4 at Week 52
Other BMD endpoints include: 
xPercent change from baseline i n total hip BMD measured using DE XA scans at Week 52 and 
at End of Treatment (EoT)
xPercent change from baseline in B MD of the lumbar spine measure d using DEXA scans of 
L2-L4 at EoT 
Ocular Endpoints : 
The primary ocular endpoint is: 
â€¢Change from baseline in the LOC S III Posterior subcapsular (P) Score at Week 52 
Other ocular endpoints include:
Confidential and Proprietary Page 15 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
â€¢Change from baseline in each scale of the LOCS III scores at We ek 28, Week 52 (Nuclear 
Opalescence (NO), Nuclear Color ( NC), and Cortical  Cataract (C)  only), and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK/2&6 ,,,JUDGHLQFUHDVHVRIÂ•& ODVVÂ•&ODVVRU
Â•&ODVVXQLWVLQHDFKRI WKHVFDOHVDW:HHN:HHN DQG(R7
â€¢Change from baseline in intraoc ular pressure (IOP) at Week 28, Week 52, and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK,23Â•PP+JDW:HHNDW:HHN DQG(R7
â€¢3URSRUWLRQRIVXEMHFWVFKDQJHIURP EDVHOLQHLQ,23RIÂ•PP+JDW :HHNDW:HHNDQG
EoT
â€¢Change from baseline in Logarithm of the Minimum Angle of Resol ution (LogMAR) visual 
acuity using Early Treatment Diab etic Retinopathy Study (ETDRS)  charts at Week 28, Week 
52, and EoT 
â€¢Change from baseline in horizont al cup-to-disc ratio at Week 28 , Week 52, and EoT 
â€¢Incidence of ocular TEAEs incl uding cataract and glaucoma 
Safety Endpoints: 
â€¢Adverse events (AEs)
â€¢12-lead electrocardiograms (ECG)
â€¢Clinical laboratory testing
â€¢Vital sign measurements
Efficacy Endpoints:
â€¢Change from baseline in average  daily rescue Ventolin HFA (albu terol sulfate) use
â€¢Percentage of days with no res cue Ventolin HFA use 
â€¢Rate of moderate or severe COPD exacerbations
â€¢Rate of COPD exacerbations of any severity
â€¢Change from baseline in: the EXACT total score, the 11-item EXA CT Respiratory 
Symptoms (E-RS) Total Score (RS-Total Score),  as well as 3 sub scale scores symptom (RS-
Breathlessness, RS-Cough and Sput um, and RS-Chest Symptoms) ove r 52 weeks and over 
each 4-week interval of the  52-week Treatment Period
Statistical Methods:   
Primary Analysis for BMD Endpoint : 
Analyses of BMD endpoints w ill be conducted on those randomized  subjects who have both 
baseline and post-baseline BMD results.
The change from baseline in BMD  of the lumbar spine at Week 52 will be analyzed using an 
Analysis of Covariance (ANCOVA) m odel with treatment group and gender as categorical 
covariates and baseline BMD, a ge, and the interaction between g ender and age as continuous 
covariates.
Primary Analysis for LOCS III Endpoint :  
Confidential and Proprietary Page 16 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Change from baseline in LOCS III (P) scores at Week 52 will be analyzed using an ANCOVA. 
The model will include treatme nt group as a fixed effect, and b aseline LOCS III (P) score, 
smoking pack years, and age as c ontinuous covariates. The model  will account for inter-eye 
correlation by including subject a nd eye (within subject) as ra ndom effects.
Two-sided 95% confidence interval s will be comput ed for pairwis e differences of BGF minus 
GFF and BFF minus GFF, and non-infe riority will be declared if the upper confidence bound is 
less than 0.5. 
Sample Size:   
Assuming a 15% rate of discon tinuation through Week 52, a subse t of 500 randomized subjects 
from the PT010006 study will provide 425 subjects with baseline  and on-treatment BMD and 
LOCS III. This sample size will  provide approximately 97% power  to demonstrate non-
inferiority of BGF MDI to GFF MDI in percent change from baseli ne in BMD for Lumbar Spine 
L2-L4 at Week 52 based on the low er limit of -2%, true differen ce of -0.3%, and SD of 4% and 
approximately 91% power  for the non-inferiority comparison of B FF MDI to GFF MDI under 
identical assumptions.  It will  provide over 99% power to demon strate non-inferiority of BGF 
MDI to GFF MDI (or BFF MDI to GFF MDI) in change from baseline in LOCS III Score (P) at 
Week 52 based on a margin of 0.5 or mor e (1-sided, alpha=0.025)  assuming no true difference in 
the means.
Data Monitoring and Clinical Endpoint Committees:   
Data Monitoring Committee :
An external Data Monitoring Committee (DMC) that was initiated in Study PT010006 will 
continue to provide s ystematic and unbiased assessment of safet y for Study PT010008.  
Members of the DMC will review d ata at predetermined intervals.   If significant safety issues 
arise in between scheduled mee tings, ad hoc meetings will be sc heduled to review the data. 
Based on the safety implications of the data, the DMC may recom mend modification or 
termination of the study.
Clinical Endpoint Committee : 
An external clinical endpoint committee (CEC) that was initiated i n Study PT010006 will 
continue to provide s ystematic and unbiased a ssessment of pre-d efined, Investigator reported 
adverse events for Study P T010008.  The committee will consist of experts who will provide a 
centralized review functioning i ndependently of Pearl. Three Cl inical Endpoint Adjudication 
Charters will outline the clinical endpoints for adjudication.
â€¢Cardiovascular- and Cerebro-vas cular (CCV) Clinical Endpoint Ad judication Charter 
â€¢Cause-Specific Mortality Clini cal Endpoint Adjud ication Charter  
â€¢Pneumonia Clinical Endpoi nt Adjudication Charter 
Date of Original Approved Protocol:  
Date of Amendment 1.0 (Version 2.0): 
Confidential and Proprietary Page 17 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
TABLE OF CONTENTS
SUMMARY OF CHANGES TO ORIGINAL PROTOCOL VERSION 1.0, DATED 
 .............................................................. ...........................................................2  
SYNOPSIS ...................................................... ............................................................... ..........13  
TABLE OF CONTENTS ............................................. ............................................................18  
LIST OF TABLES ................................................ ............................................................... ....23  
LIST OF FIGURES ............................................... ............................................................... ...23  
LIST OF APPENDICES ............................................ ..............................................................2 3 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................ ..........................24  
TRADEMARK INFORMATION ......................................... ..................................................26  
1 INTRODUCTION .................................................. .........................................................27  
1.1 Study Rationale ............................................... .......................................................28  
2 STUDY OBJECTIVES .............................................. ......................................................29  
2.1 Primary Objective ............................................. .....................................................29  
2.2 Secondary Objectives........................................... ..................................................29  
3 STUDY ENDPOINTS ............................................... ......................................................30  
3.1 Bone Mineral Density Endpoints ................................ ...........................................30  
3.1.1  Primary Bone Mineral Density Endpoint ......................... ...........................30  
3.1.2  Other BMD Endpoints ........................................... ......................................30  
3.2 Ocular Endpoints .............................................. .....................................................30  
3.2.1  Primary Ocular Endpoint ....................................... ......................................30  
3.2.2  Other Ocular Endpoints ........................................ .......................................30  
3.3 Safety Endpoints .............................................. ......................................................31  
3.4 Efficacy Endpoints ............................................ .....................................................31  
4 INVESTIGATIONAL PLAN .......................................... ................................................32  
4.1 Overall Study Design and Plan ................................. .............................................32  
5 STUDY POPULATION SELECTION AND WITHDRAWAL CRITERIA ............ .....35  
5.1 Inclusion Criteria ............................................ .......................................................35  
5.2 Exclusion Criteria ............................................ ......................................................35  
5.2.1  Bone Mineral Density Criteria applied to either hip or lumbar r egion ........35  
5.2.2  Ophthalmologic Criteria applied to either eye ................. ............................35  
5.3 Subject Identification ........................................ .....................................................36  
5.4 Prior, Concomitant, and Pr ohibited Medications ................ ...................................36  
5.4.1  Allowed Concomitant Medications  to Treat a COPD Exacerbation .. .........36  
5.4.2  Prohibited COPD Medications ................................... .................................36  
5.4.3  Other Prohibited Medications .................................. ....................................37  
5.5 Other Restrictions, Illicit Drugs, or Drugs of Abuse .......... ...................................38  
Confidential and Proprietary Page 18 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
5.5.1  Illicit Drugs ................................................. .................................................38  
5.5.2  Dietary Restrictions .......................................... ...........................................38  
5.6 Smoking Status ................................................ ......................................................39  
5.7 Reasons and Procedures for Early D iscontinuation from the Study  ......................39  
5.7.1  Reasons for Discontinuation ................................... .....................................39  
6 LABELING, PACKAGING, STORAGE, DISPENSING, AND RETURN OF 
CLINICAL SUPPLIES ............................................. .......................................................41  
6.1 Subject Information ........................................... ....................................................41  
6.2 Product Descriptions .......................................... ....................................................41  
6.3 Primary Packaging and La beling Information .................... ...................................42  
6.4 Secondary Packaging and Labeling Information (Box) ............ .............................43  
6.5 Emergency Unblinding of Treatment Assignment .................. ..............................43  
6.6 Storage Requirements .......................................... ..................................................44  
6.7 Instructions for Preparation of T reatments for Administration a nd Dispensing....44  
6.7.1  BGF MDI, GFF MDI, BFF MDI ..................................... ............................44  
6.7.2  Ventolin HFAÂ® .............................................................. ..............................44  
6.8 Drug Accountability/Return of Clinical Supplies ............... ...................................45  
7 STUDY PROCEDURES .............................................. ...................................................46  
7.1 Bone Mineral Density Assessments............................... ........................................46  
7.2 Ophthalmologic Assessments .................................... ............................................46  
7.3 Subject Electronic Diary (eDiary) Data Collection ............. ..................................47  
7.3.1  Rescue Medica tion Usage ....................................... .....................................48  
7.3.2  Medication Compliance ......................................... ......................................48  
7.3.3  Recording of Dose Indicator Reading............................ ..............................48  
7.3.4  Major/minor Symptom Worsening  Assessment and Alert System ..... ........49  
7.4 COPD Exacerbations ............................................ .................................................49  
7.4.1  Severity of COPD Exacerbation ................................. .................................50  
7.4.2  Duration of COPD exacerbation ................................. .................................50  
7.4.3  Approach for Capturing COPD Exacerbations ..................... .......................51  
7.4.4  Other Information ............................................. ...........................................51  
7.4.5  Investigator-Judged COPD Exacerbations ........................ ..........................51  
7.5 Subject Questionnaire ......................................... ...................................................51  
7.6 Safety Assessments ............................................ ....................................................52  
7.6.1  Medical/Surgical History a nd Physical Examination ............. .....................52  
7.6.2  Vital Sign Measurements ....................................... ......................................52  
7.6.3  12-Lead Electrocardiogram ..................................... ....................................52  
7.6.4  Clinical Laboratory Tests ..................................... ........................................53  
7.6.4.1  Hematology .................................................... ....................................54  
Confidential and Proprietary Page 19 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
7.6.4.2  Clinical Chemistry ............................................ .................................54  
7.6.4.3  Urinalysis .................................................... .......................................55  
7.6.4.4  Pregnancy Test ................................................ ...................................55  
7.7 Adverse Events ................................................ ......................................................56  
7.7.1  Performing Adverse Ev ents Assessments ......................... ...........................56  
7.7.2  Adverse Event Definitions ..................................... ......................................56  
7.7.3  Severity ...................................................... ..................................................57  
7.7.4  Relationship .................................................. ...............................................57  
7.7.5  Chronic Obstructive Pulmonary Disease Exacerbations ........... ..................58  
7.7.6  Adverse Events of Special Interest ............................ ..................................58  
7.7.6.1  LABA and LAMA Effects ......................................... ........................58  
7.7.6.2  Local Steroid Effects.......................................... ................................58  
7.7.6.3  Pneumonia...................................................... ....................................58  
7.7.6.4  Paradoxical Bronchospasm ...................................... ..........................59  
7.7.7  Major Adverse Cardiovasc ular Events (MACE) .................... .....................59  
7.7.8  Clinical Laboratory Adverse Events ............................ ................................59  
7.7.9  Serious Adverse Events ........................................ .......................................60  
7.7.9.1  Reporting of Serious  Adverse Events ........................... .....................61  
7.7.9.2  Supplemental Investigations of SAEs ........................... .....................61  
7.7.9.3  Post-Study Follow-Up of Adverse Events ........................ .................61  
7.7.9.4  Notification of Post-Study S erious Adverse Events ............. .............61  
7.7.9.5  Investigational Research Board/Independent Ethics Committee 
Notification of Serious Adverse Events ........................ .....................61  
7.7.9.6  Health Authority Sa fety Reports ............................... .........................62  
7.7.10  Overdose ...................................................... ................................................62  
7.7.11  Pregnancy ..................................................... ................................................62  
7.7.12  Use of Steroids during the Study .............................. ...................................62  
7.7.13  Clinical Endpoint Committee ................................... ...................................63  
7.7.13.1  Cardiovascular and Cerebrovasc ular (CCV) Clinical Endpoint 
Adjudication Charter .......................................... ................................63  
7.7.13.2  Cause-Specific Mortality Clini cal Endpoint Adjudication Charter  ...63  
7.7.13.3  Pneumonia Clinical Endpoint  Adjudication Charter .............. ...........63  
7.7.14  Data Monitoring Committee ..................................... ...................................63  
7.8 Termination of the Study ...................................... .................................................64  
8 STUDY ACTIVITIES .............................................. .......................................................65  
8.1 Baseline Assessments .......................................... ..................................................67  
8.2 Randomization ................................................. ......................................................67  
8.3 Visit 10b ..................................................... ............................................................67  
8.4 Visits 11 (Week 28) ........................................... ....................................................68  
8.5 Visit 12 (Week 36) ............................................ .....................................................69  
Confidential and Proprietary Page 20 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
8.6 Visit 13 (Week 44) ............................................ .....................................................70  
8.7 Visit 14 (Week 52; Final Visit) ............................... ...............................................72  
8.8 Unscheduled Visit and T reatment Discontinua tion/Withdrawal Visi t ..................73  
8.9 Follow-up Telephone Call ...................................... ...............................................73  
8.10  Vital Status Confir mation at Week 52 .......................... .........................................73  
8.11  Completion of Study ........................................... ...................................................74  
9 PLANNED STATISTICAL METHODS ................................... .....................................75  
9.1 Introduction .................................................. ..........................................................75  
9.2 Protocol Variables ............................................ ......................................................75  
9.2.1  Study Endpoints ............................................... ............................................75  
9.2.2  Primary Bone Mineral Density Endpoint ......................... ...........................75  
9.2.3  Other Bone Mineral Density Endpoints .......................... .............................75  
9.2.4  Primary Ocular Endpoint ....................................... ......................................76  
9.2.5  Other Ocular Endpoints ........................................ .......................................76  
9.2.6  Safety Endpoints .............................................. ............................................76  
9.2.7  Efficacy Endpoints ............................................ ...........................................76  
9.3 Study Populations ............................................. .....................................................77  
9.4 Safety Analyses ............................................... .......................................................77  
9.4.1  Analysis of BMD Endpoints ..................................... ...................................78  
9.4.1.1  Percent change from baseline in B MD of the lumbar spine measure d 
using DEXA scans of L2-L4 ..................................... .........................78  
9.4.1.2  Percent change from baseline  in total hip BMD of the hip measur ed 
using DEXA scans .............................................. ...............................78  
9.4.2  Analysis of Ocular Endpoints .................................. ....................................78  
9.4.2.1  Change from baseline in each of  the LOCS III (NO, NC, C, and P)  
scores......................................................... .........................................78  
9.4.2.2  Proportion of subjects with LOCS I ,,JUDGHLQFUHDVHVRIÂ•&ODVV
Â•&ODVVRUÂ•&OD VVXQLWVLQHDFKRIWKHVF DOHV ......78  
9.4.2.3  Change from baseline in intraocular pressure (IOP) ............ ..............79  
9.4.2.4  3URSRUWLRQRIVXEMHFWVZLWK,23 Â•PP+JDQGWKHSURSRUWLRQRI
subjects with chan JHIURPEDVHOLQHLQ,23RIÂ•PP+J  ..................79  
9.4.2.5  Change from baseline in LogMAR visual acuity using ETDRS charts 79 
9.4.2.6  Change from baseline in horizontal cup-to-disc ratio .......... ..............79  
9.4.2.7  Incidence of ocular TEAEs inc luding cataract, glaucoma ........ .........79  
9.4.3  Adverse Events ................................................ ............................................79  
9.4.4  Cardio- and Cerebrovascular Eve nts Determined by Adjudication 
Committee ..................................................... ...............................................79  
9.4.5  Pneumonia Events Determined by Adjudication Committee ......... .............80  
9.4.6  Clinical Laboratory Measurements .............................. ................................80  
9.4.7  Vital Signs ................................................... .................................................80  
Confidential and Proprietary Page 21 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
9.4.8  Electrocardiograms ............................................ ..........................................81  
9.4.9  Exposure ...................................................... ................................................81  
9.5 Analyses of Efficacy Endpoints ................................ .............................................81  
9.5.1  Rescue Ventolin HFA Use ....................................... ....................................81  
9.5.2  Percentage of Days with No Rescu e Ventolin HFA Use over the Tre atment 
Period ........................................................ ...................................................81  
9.5.3  Chronic Obstructive Pulmonary Disease Exacerbations ........... ..................81  
9.5.4  Exacerbations of Chronic Pulmona ry Disease Tool (EXACT) ....... ............82  
9.5.5  Control of Type I Error ....................................... .........................................83  
9.6 Randomization ................................................. ......................................................83  
9.7 Experimental Design ........................................... ...................................................83  
9.8 Sample Size ................................................... .........................................................83  
9.9 Data Validation and T ransformation ............................ .........................................83  
9.10  Analysis Plan ................................................. ........................................................83  
9.11  Handling of Missing Data ...................................... ................................................83  
9.12  Statistical Software .......................................... ......................................................83  
10 ADMINISTRATIVE CONSIDERATIONS ................................. ...................................84  
10.1  Regulatory Authority Approval ................................. ............................................84  
10.2  Ethical Conduct of the Study and Institutional Review Board or Independent 
Ethics Committee Approval ..................................... ..............................................84  
10.3  Subject Information and Consent................................ ...........................................84  
10.4  Laboratory Accreditation ...................................... .................................................85  
10.5  Confidentiality ............................................... ........................................................85  
10.5.1  Confidentiality of Data ....................................... .........................................85  
10.5.2  Confidentiality of Subject/Patient Records .................... ..............................85  
10.6  Quality Control and Assurance ................................. .............................................85  
10.7  Data Management ............................................... ...................................................85  
10.8  Study Monitoring .............................................. .....................................................86  
10.9  Retention of Data ............................................. ......................................................87  
10.10  Financial Disclosure........................................... ....................................................87  
10.11  Investigator's Final Report ................................... ..................................................87  
10.12  Publication Policy ............................................ ......................................................87  
11 REFERENCE LIST ................................................ .........................................................89  
12 APPENDICES ................................................. ............................................................... ....90  
Confidential and Proprietary Page 22 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
LIST OF TABLES
Table 5-1.  Prohibited COPD Medications ................................... ...............................36  
Table 5-2.  Other Respiratory/Na sal Medications ........................... .............................37  
Table 5.3.  Non-COPD Medications Allowe d Under Certain Conditions ......... ..........37  
Table 6-1.  Product Descriptions .......................................... ........................................41  
Table 6-2.  Description of Boxes........................................... .......................................43  
Table 7-1.  Clinical Laboratory Tests ..................................... ......................................55  
Table 8-1.  Schedule of Events ............................................ .........................................66  
LIST OF FIGURES
Figure 1.  Study Design .................................................. ............................................34  
LIST OF APPENDICES
Appendix 1  Dose Indicator Reading......................................... .....................................90  
Appendix 2  Subject Instructions for Use of  BGF MDI, GFF MDI, and BFF MDI .. ...91  
Appendix 3  Instructions for Use of Ventoli n HFA Inhalation Aerosol Device ..........100  
Appendix 4  Exacerbations of Chronic Obstructive Pulmonary Disease Tool (EX ACT) 
â€“ Patient-Repor ted Outcomes .................................... ..............................107  
Appendix 5  Sponsor Signature ............................................. .......................................111  
Appendix 6  Investigatorâ€™s Signature ...................................... .....................................112  
Confidential and Proprietary Page 23 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
AE Adverse event
AESI Adverse event of special interestANOVA Analysis of CovarianceBD BudesonideBFF Budesonide and for moterol fumarate
BGF Budesonide, glycopyrroni um, and formoterol fumarate
BID bis in die , twice daily
BMD Bone Mineral DensityCCV Cardio- and cerebro-vascular CFR Code of Federal RegulationsCONSORT Consolidated Standa rds Of Reporting Trials
COPD Chronic obstructiv e pulmonary disease 
DEXA Dual Energy X-ray AbsorptiometryDMC Data Monitoring CommitteeECG Electrocardiogram eCRF Electronic case report formEoT End of TreatmentETDRS Early Treatment Dia betic Retinopathy Study
FDA Food and Drug AdministrationFF Formoterol fumarateGCP Good Clinical PracticeGFF Glycopyrronium and formoterol fumarateGOLD Global Initiative for Chronic Obstructive Lung DiseaseHFA HydrofluoroalkaneIEC Independent Ethics CommitteeIOP Intraocular PressureIRB Institutional Review BoardLOCS III Lens Opacities Classification System III
Confidential and Proprietary Page 24 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
LogMAR Logarithm of the Minimum Angle of Resolution
MACE Major adverse cardiovascular eventsMDI Metered dose inhalerPRO Patient-reported outcomePSC Posterior Subcapsular CataractSAE Serious adverse event
SD Standard deviation
TBH Turbuhaler
TC Telephone call
Confidential and Proprietary Page 25 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
TRADEMARK INFORMATION 
Trademarks Not Owned By P earl Therapeutics, Inc.
Oxis
Spiriva 
Symbicort 
Ventolin
Turbuhaler 
Confidential and Proprietary Page 26 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
1 INTRODUCTION
Chronic obstructive pulmonary dis ease (COPD) is a common prevent able and treatable disease
characterized by persistent ai rflow limitation that is usually progressive and a ssociated with an 
enhanced chronic inflammatory r esponse in the airways and the l ung to noxious particles or 
gases.  Exacerbations and co-mo rbidities contribute to the overa ll severity in individual patients.  
Chronic obstructive pulmonary dis ease is a leading cause of morb idity and mortality worldwide
and results in significant econo mic and social burden that is b oth substantial and increasing.  
Pharmacologic therapy in COPD is  used to reduce symptoms, reduce the frequency and severity 
of exacerbations, and improve hea lth status and exercise tolera nce [Global Initiative for Chronic 
Obstructive Lung Disease (GOLD, 2014) ; Japanese Respiratory Society (JRS, 2013) .
Bronchodilator medications are cen tral to the symptomatic manag ement of COPD.  The principal 
EURQFKRGLODWRUWUHDWPHQWVDUHÈ• 2-agonists, anticholinergics, and methylxanthines used as 
monotherapy or in combination.  Tr eatment with long-acting bron chodilators is more convenient 
and more effective at producing ma intained symptom relief than treatment with short-acting 
bronchodilators. 
Regular treatment with inhaled corticosteroids (ICS) improves s ymptoms, lung function, and 
quality of life and reduces the frequency of exacerbations in s ubjects with COPD with a forced 
expiratory volume in 1 second (FEV 1) value of <60% of predicte d.  Withdrawal from treatment 
of ICS may lead to exacerbations  in some patients.  When combin ed with a long-acting 
È•2-agonist (LABA), an ICS is more effective than the individual c omponents in improving lung 
function, quality of life, and re ducing exacerbations in subjec ts with moderate to very severe 
COPD [GOLD, 2014] .   
Pearl Therapeutics, Inc. (hereinafter referred to as Pearl) is developing the fixed-dose ICS/ long-
acting anti-muscarinic agent (LA MA)/LABA triple combination pro duct, Budesonide, 
Glycopyrronium, and Formoterol F umarate Inhalation Aerosol (PT0 10), hereafter referred to as 
budesonide, glycopyrronium, and f ormoterol fumarate metered dos e inhaler (BGF MDI), for the 
treatment of patients wi th COPD.  Budesonide and Formoterol Fum arate Inhalation Aerosol 
(PT009, hereinafter referred to a s budesonide and formoterol fu marate (BFF) MDI is also being 
developed as a twice daily (BID)  fixed dose ICS/LABA treatment for patients with COPD.
Glycopyrronium and Formoterol F umarate Inhalation Aerosol (PT00 3) hereinafter referred to as 
glycopyrronium and formoterol fuma rate (GFF) MDI is being develo ped as a BID maintenance 
bronchodilator treatment  in patients with COPD.
Budesonide is a well-establishe d corticosteroid a pproved worldw ide in monotherapy and 
combination therapies for treatme nt of asthma and allergic rhin itis.  It is available in both 
intranasal and orally inhaled f ormulations.  Inhaled budesonide  in combination with formoterol 
fumarate dihydrate, i.e., Symbic ort is approved for use in pati ents with COPD.  
Glycopyrronium is a LAMA whic h exerts its bronchodilatory effec t via muscarinic receptors 
located on smooth muscle cells w ithin the trachea and bronchi.  Glycopyrronium is approved in 
many countries in multiple formu lations for different indicatio ns, including for t he treatment of 
COPD.  
Confidential and Proprietary Page 27 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Formoterol fumarate is a selectiv e LABA approved worldwide for use in asthma and COPD.  In 
addition, formoterol fumarate is also approved worldwide in com bination with budesonide (e.g., 
SymbicortÂ® MDI, SymbicortÂ® TurbuhalerÂ®(TBH [AstraZeneca, LP]) for use in patients with 
asthma and COPD.  When i nhaled, formoterol fu marate acts locall y in the lung as a 
EURQFKRGLODWRU)RUPRWHUR OIXPDUDWHVWLPXODWHVÈ• 2-adrenoreceptors in the airways, inducing 
airway smooth muscle relaxation a nd reducing or preventing bron choconstriction. 
1.1 Study Rationale 
Patients with COPD are frequently treated with ICS; the impact of ICS use on potential fracture 
risk is not consistent acr oss published literature [Lehouck, 2011; Weldon, 2009 ; Christensson,
2008] . Studies in adults with COPD ha ve produced a wide range of res ults in support of the 
direct effect of ICS on bone miner al density (BMD) and fracture  risk.
It has also been reported that c orticosteroid treatment can lea d to multiple ocular effects, 
including cataracts, increased i ntraocular pressure (IOP) and g laucoma. Furthermore, as the 
majority of the COPD population i s elderly, these observed ocul ar changes are more likely to be 
predominant in an elderly popul ation. For example, in the TORCH  safety sub-study, the 
background prevalence of cataracts was high in COPD patients (6 8.5-75.3% at Screening) 
[Calverley, 2007] .  
As a result of the increased o ccurrence of cataracts, IOP, and glaucoma and the increased risk of 
bone disorders in patients wit h COPD, definitive ocular and bon e mineral density assessments 
are included in this 1-year safety study.
Confidential and Proprietary Page 28 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
2 STUDY OBJECTIVES
2.1 Primary Objective 
xTo evaluate the effect of BGF MDI, GFF MDI, and BFF MDI on bone  mineral density 
(BMD) over 52 weeks 
â€¢To evaluate the effect of BGF MDI, GFF MDI, and BFF MDI on ocul ar assessments over 52 
weeks
2.2 Secondary Objectives
xTo assess the safety and tolerab ility of BGF MDI, GFF MDI, and BFF MDI 
Confidential and Proprietary Page 29 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
3 STUDY ENDPOINTS
All assessments are relative t o baseline assessments performed during the Study PT010006 
Screening Period (betw een Visit 1 and Visit 4).   
3.1 Bone Mineral Density Endpoints
3.1.1 Primary Bone Mineral Density Endpoint 
â€¢Percent change from baseline in B MD of the lumbar spine measure d using DEXA scans of 
L2-L4 at Week 52
3.1.2 Other BMD Endpoints
xPercent change from baseline i n total hip BMD measured using DE XA scans at Week 52 and 
at End of Treatment (EoT)
xPercent change from baseline in B MD of the lumbar spine measure d using DEXA scans of 
L2-L4 at EoT 
3.2 Ocular Endpoints
3.2.1 Primary Ocular Endpoint
â€¢Change from baseline in the LOCS III (P) Score at Week 52
3.2.2 Other Ocular Endpoints
â€¢Change from baseline in each scale of the LOCS III scores at We ek 28, Week 52 (NO, NC, 
and C only), and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK/2&6 ,,,JUDGHLQFUHDVHVRIÂ•& ODVVÂ•&ODVVRU
Â•&ODVVXQLWVLQHDFKRI WKHVFDOHVDW:HHN:HHN DQG(R7
â€¢Change from baseline in intraoc ular pressure (IOP) at Week 28, Week 52, and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK,23Â•PP+JDW:HHNDW:HHN DQG(R7
â€¢3URSRUWLRQRIVXEMHFWVFKDQJHIURP EDVHOLQHLQ,23RIÂ•PP+JDW :HHNDW:HHNDQG
EoT
â€¢Change from baseline in LogMAR visual acuity using ETDRS charts  at Week 28, Week 52, 
and EoT 
â€¢Change from baseline in horizont al cup-to-disc ratio at Week 28 , Week 52, and EoT
â€¢Incidence of ocular TEAEs including cataract and glaucoma
Confidential and Proprietary Page 30 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
3.3 Safety Endpoints
â€¢Adverse events (AEs)
â€¢12-lead electrocardiograms (ECGs)
â€¢Clinical laboratory testing
â€¢Vital sign measurements
3.4 Efficacy Endpoints
â€¢Change from baseline in average  daily rescue Ventolin HFA (albu terol sulfate) use
â€¢Percentage of days with no res cue Ventolin HFA use 
â€¢Rate of moderate or severe COPD exacerbations
â€¢Rate of COPD exacerbations of any severity
â€¢Change from baseline in: the E XACT total score , the 11-item EXA CT Respiratory 
Symptoms (E-RS) Total Score (RS-Total Score),  as well as 3 sub scale scores symptom (RS-
Breathlessness, RS-Cough and Sput um, and RS-Chest Symptoms) ove r 52 weeks and over 
each 4-week interval of the  52-week Treatment Period
Confidential and Proprietary Page 31 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
4 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan 
This is a randomized, double-b lind, parallel-group, 52-week, ch ronic-dosing, multi-center 
supplemental study to assess the effects of PT010, PT009, and P T003 on bone mineral density 
(BMD), ocular assessments, and s afety and tolerability in subje cts with moderate to very severe 
COPD.  This 52-week study will be  conducted in a sub-set of sub jects participating in Study 
PT010006. Approximately 70 sites are  planned to participate in the study, contributing 
approximately 8 subjects per site .  Across these sites, it is pl anned that approximately 
500 subjects randomized to double-b lind treatment only will be included in Study PT010008 
to provide approximate ly (425) subjects who w ill complete the s tudy at Visit 14 (Week 52). 
Subjects will receive the same tr eatment (BGF MDI, GFF MDI, or BFF MDI) they were 
randomized to in Study PT010006. S ubjects randomized to open-lab el Symbicort TBH will not 
be enrolled in this study, howev er, since baseline BMD and ocul ar assessments will be 
performed prior to randomizati on all subjects who will eventual ly be randomized to Symbicort 
TBH will have a baselin e assessment. The entire study period is  scheduled to take approximately 
58 weeks for most subjects. 
This safety study will evaluate the effects of BGF MDI, BFF MDI , and GFF MDI on bone 
mineral density (BMD) measurement (Johnell, 2002 ) and lenticular opacity (Chylack, 1993 ) and 
ocular pressure assessments. 
Baseline and demographic charact eristics collected in Study PT0 10006 will be used for subjects 
participating in this study. Bas eline assessments (BMD, lenticu lar opacity, fundoscopic 
examination, intraocular pre ssure, pupil dilatation, and visual  acuity assessments) will be 
performed prior to randomizati on in Study PT010006.  If the fir st two BMD scans differ by more 
than 5% (as determined by the lo cal facility) for either site ( i.e. first two hip or  first two lumbar 
sites) a third scan should be obt ained. The screening period ma y be extended up to a maximum 
of 21 days if additional time is n eeded to complete the assessm ents. A separate informed consent 
will be obtained for subjects pa rticipating in Study PT010008 p rior to any study PT010008 
procedures.   
Subjects participating in Stu dy PT010008 who complete visit 10a  of Study PT010006 will 
transition to the remaining 28 week s of treatment by completing  Visit 10b (Week 24). Post-
baseline lenticular opacity, f undoscopic examination, intraocul ar pressure, and visual acuity 
assessments will be performed pr ior to Visit 11 (Week 28), Visi t 14 (Week 52) and Treatment 
Discontinuation/Withdrawal Vis it. A post-baseline BMD assessmen t will be performed prior to
Visit 14 (Week 52) and Treatment D iscontinuation/Withdrawal Vis it. Subjects will return to the 
clinic at Visit 12 (Week 36), a nd Visit 13 (Week 44) to return used medication and obtain new 
study drug. Subjects will retur n to the clinic a t Visit 14 (Wee k 52) to complete final study visit 
procedures. 
All subjects will continue to r eceive sponsor-provided VentolinÂ®HFA (albuterol sulfate 
inhalation aerosol) for resc ue use throughout the study. 
After Visit 14 (Week 52), a fo llow-up telephone call will be pe rformed at least 14 days after the 
last study drug dose. For subject s who withdraw consent, schedu le a follow-up telephone call at 
Confidential and Proprietary Page 32 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0,
least 14 days after the last stud y drug dosing, if the final vi sit is performed >14 days post last 
study drug dosing, a follo w-up TC will not be required.   
If a subject choos esnot to continue with study asse ssments, at a minimum the subjec t will 
complete the Treatment Discontinuation/Withdrawal Visit (refer to Table 8-1) . For subjects 
discontinuing treatment at any time during the study including the time during which they are 
participating in Study PT 010006, lenticular opacity, fundoscopi c examination, intraocular 
pressure, pupil dilation and visual  acuity assessments should b e performed as soon as possible.  
For subjects discontinuing tre atment after Visit 10b (Week 24),  BMD assessments should also be 
obtained as soon as possible (Not e: Subject who discontinues pr ior to Visit 10b will not complete 
BMD assessments).  These subjects will return to appropriate ma intenance COPD medications, 
per the investigators discretion . A follow-up telephone call will  be performed at least 14 days 
after the last study drug dose. I n the event the Treatment Disc ontinuation/Withdrawal Visit is 
performed >14 days post last study drug dosing, a follow-up TC will not be required. These 
subjects will be followed for v ital status at 52 weeks post-ran domization in accordance with the 
informed consent. 
An overall study design is summarized and displayed in Figure 1.  
Confidential and Proprietary Page 33 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Figure 1. Study Design  
Confidential and Proprietary Page 34 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
5 STUDY POPULATION SELECTION AND WITHDRAWAL 
CRITERIA
5.1 Inclusion Criteria 
Subjects eligible for enrollment in the study must meet all of t he following criteria:
1. Give their signed written infor med consent to participate. 
2. Subjects must have agreed t o participate in Study PT010006. 
5.2 Exclusion Criteria 
Subjects who meet any of the follo wing criteria will be exclude d from the study (please see 
the exception noted below the ophthalmologic criteria  Section 5.2.2).
5.2.1 Bone Mineral Density Criteria applied to either hip or lumb ar region
1. Severe osteoporosis  
2. T-score < -2.5 at baseline  3. Subjects unable to achieve an acceptable scan (e.g. due to th e patientâ€™s inability to be 
stable during the procedure , due to limitation of scanning equi pment ( ~300 lbs or ~136 
kgs) or other characteristics) 
5.2.2 Ophthalmologic Criteria applied to either eye  
4. Inability to dilate pupil >6 mm 
5. IOP >21mmHg  (lowest of the 3 readings) 
Note: Subjects with IOP >21mmHg may be  treated and re-tested during t he screening period. 
If the re-test measurements for  IOP <21mmHg this subject may be  eligible  
6. Subjects who have an implanted a rtificial intraocular lens, i .e., subjects who have 
undergone, or are scheduled to undergo, cataract removal surger y. 
 
NOTE:  Subjects who meet none  of the bone mineral density exclusion criteria but who meet 
one or more ophthalmologic exclusion criteri a may be permitted to continue in the study. 
Such subjects would undergo all stud y planned assessments excep t they would undergo no 
further ophthalmologic exam s (all tests included in  Section 7.2 ) during the randomized 
treatment period. Additio nally such subjec ts would be permitted  to continue in the study 
provided that the following  2 conditions are satisfied: 
â€¢,23LVÂ”PP+JHLWKHUZLWKRUZLWKRXW treatment  
â€¢In the opinion of the optometris t/ophthalmologist, the subject does not have a condition 
(e.g., advanced glaucoma) that th e eye health of the subject co uld be jeopardized by 
continued particip ation in the study  
Confidential and Proprietary Page 35 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
5.3 Subject Identification 
All subjects who participate in t his study will maintain the un ique screening identification 
number and unique subject randomiz ation number assigned to them  for participation in Study 
PT0100006. 
5.4 Prior, Concomitant, and Prohibited Medications  
Any additions, deletions, or chang es in the dose of these medic ations while in the study 
should be entered on the CRF.  Any c urrent ongoing medications,  including OTC drugs and 
herbal supplements, will be allo wed provided they are not prohi bited by the protocol (refer 
toSection 5.4)  and are approved by the inve stigator.  Subjects should also be  instructed to 
contact the investigator if they develop any illnesses.  
All concomitant medications t aken during the study will be reco rded on the Concomitant 
Medications CRF page with indi cation, total daily dose, and dat es of drug administration. 
5.4.1 Allowed Concomitant Medications to Treat a COPD Exacerbati on
Medications to treat an exacer bation should not be used for mor e than 14 days. Recent data 
have suggested that treatment w ith systemic steroids for shorte r periods of time results in 
similar outcomes with less syste mic steroid exposure. Therefore , it is recommended that 
subjects are treated with a 5 day course of steroids and no lon ger than 14 days.
5.4.2 Prohibited COPD Medications 
The following medications used f or the treatment  of COPD are no t permitted during this 
study.  These medications mus t have been discontinued during th e Screening Period of Study 
PT010006 and are prohibited during this supplemental study (Table 5-1) . 
Table 5-1. Prohibited COPD Medications 
Class of medication
LAMAs
Short-acting muscarinic antagonists (SAMA)
LABAs (inhaled)
Fixed-combinations of LABA/LAMA
Fixed-combinations of LABA/ICS
Fixed-combinations of SABAs and SAMAs 
SABAsa
2UDOÈ• -agonists
Theophylline (total daily dose >400 mg/day)b
Abbreviations:  ICS=inhaled corticosteroid; LABA=long- DFWLQJÈ• 2-agonist; LAMA=long-acting muscarinic antagonist; SABA=short-
DFWLQJÈ• 2-agonist; SAMA=short-acting muscarinic antagonist
aO t h e r  t h a n  s p o n s o r - p r o v i d e d  o p e n - l a b e l  V e n t o l i n  H F A .      
bTheophylline (<400 mg/day) is permitted provided the subject ha s been on a stable dose of therapy for at least 4 weeks prior t o 
Randomization in Study PT010006.
Confidential and Proprietary Page 36 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Note:   
â€¢During the Treatment Period ( Visit 10b to Visit 14), subjects m ay be treated with 
systemic corticosteroids if required
â€¢Subjects who are steroid depe ndent and maintained on an equival ent of up to 5 mg oral 
SUHGQLVRQHSHUGD\RUÂ”PJRUDOSUHGQL sone every other day are permitted to enroll in 
the study provided they have be en on a dose of oral steroids th at remains consistent and 
does not exceed this threshold for  the last two weeks prior to randomization (Visit 4) in 
Study PT010006 
The following respiratory med ications are not permitted during this study (Table 5-2) .
Table 5-2. Other Respiratory/Nasal Medications 
Class of Medication
Leukotriene antagonists (e.g., zafirlukast, montelukast and zil ueton)
Cromoglycate
Nedocromil
Ketotifena
a Ketotifen eye drops are allowed
5.4.3 Other Prohibited Medications
Table 5.3 lists certain non-COPD  medications that can be used u nder the stated conditions 
during this study. Each concomitant drug must be individually a ssessed against all exclusion 
criteria.  If in doubt, the Inves tigator should contact Pearlâ€™s  Medical Monitor before 
randomizing a subject or allowing  a new medication to be starte d:
Table 5.3. Non-COPD Medications A llowed Under Certain Conditions
Medications Allowed Under Certain 
ConditionsCondition 
SSRIs or SNRIs Treatment reg imen has been stable for at 
least 4 weeks prior to Visit 1 and not altered during the Screening Period, and does not exceed the maximum recommended dose
Intranasal corticosteroids, intranasal antihistamines, or com bination thereof Administered at cons tant dose and dosing 
regimen for at least 7 days prior to Screening (Visit 1) and during the Screening Period 
Abbreviations:  COPD=chronic obstructive pulmonary disease; SNR I=serotoninâ€“norepinephrine reuptake 
inhibitors; SSRI= selective serotonin reuptake inhibitors
Subjects requiring med ications presented in Table 5-4 are prohibited from participating in 
this study. Subjects who recentl y discontinued use of these med ications may be considered
for study enrollment providing they have met the minimum Washou t Period prior to Visit 1. 
These medications are prohibite d throughout the course of the s tudy, and, should a subject 
Confidential and Proprietary Page 37 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
require use of any of the listed m edications, the investigator should evaluate the 
appropriateness of c ontinuing the subject in the study. 
Table 5.4. Prohibi ted Medications
5.5 Other Restrictions, Illicit Drugs, or Drugs of Abuse 
5.5.1 Illicit Drugs
Illicit drugs or drugs of abuse will not be allowed from Visit 10b to Visit 14 or to whenever 
the subject withdraws from the study.  If any illicit drugs or drugs of abuse are used by the 
subject during the study, the da tes of use and the amount will be documented and the subject 
will be discontinued a t the discretion of t he investigator.  Me dical marijuana is not an 
exclusionary drug if used for m edical purposes, and there is no  change in the dose or 
frequency of consumption. 
5.5.2 Dietary Restrictions
Subjects must not ingest xanthine  and/or xanthine analogue (caf feine)-containing foods and 
beverages for at least 6 hours pr ior to each study visit and fo r the duration of each study visit.  
Examples of such products include  coffee, tea, chocolate, and c ola.  Decaffeinated beverages 
are acceptable.Prohibited Medications
Any drug with potential to significantly prolong the QT interva l 
Other investigational drugs
Non-selective beta-blocking agents (exception Carvedilol )
Cardiac antiarrhythmics Class Ia, III )
Anticonvulsants for seizure disordera
Anticonvulsants for other indicationsa
Tricyclic antidepressantsb
Monoamine oxidase inhibitors
Anti-tumor QHFURVLVIDFWRUÄ®71)Ä®DQWLERGLHVHJLQIOL[LPDEDQGDQ\ RWKHUPHPEHUVRIWKLVFODVVRIGUXJV
Monoclonal antibodies
Antipsychotic drugs b
Systemic calcineurin inhibitors, systemic antifungal agents, pr otease inhibitors and cimetidine
Systemic anticholinergicsc
Illicit drugs or drugs of abuse
Chinese complementary and alternative bronchodilatory medicines  (CAM), i.e., herbal therapies 
(e.g., Astragalus membranaceus [ huÃ¡ng qÃ­] , Panax ginseng [ginseng products] and Cordyceps sinensis. A. 
membranaceus [ghost moth caterpillar fungus])d
Note: Benzodiazepines are not exclusionary.
a Anticonvulsants for seizure or other indications allowed provid ed the patient was treated with this class of medications 
during  Study PT010006
b Antipsychotic agents and tricyclic antidepressants used for pre viously diagnosed underlying medical conditions are allowed 
if, in the opinion of the Investigator, there are no concerns r egarding patient safety, and if the patient has been on a stabl e 
dose for at least 6 weeks.
c Systemic anticholinergics are allowed provided the patient was t reated with this class of medications during  Study 
PT010006
d,Requires case-by-case review by the Investigator to determine a ppropriate wash-out period, if needed.
Confidential and Proprietary Page 38 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
5.6 Smoking Status 
Changes in a subjectâ€™s smoking status (e.g., stopping or re-sta rting smoking) may have an 
impact on the efficacy outcome meas ures.  At all visits the sub ject will be asked about any 
recent change in their smoking s tatus (i.e., whether a subjectâ€™ s status has changed from 
smoker to non-smoker or vice versa) .  Smoking status changes du ring the 28-week Treatment 
Period will be captured in the e CRF, but the subject will be pe rmitted to continue in the 
study.  Subjects will be require d to refrain from smoking (incl uding medical marijuana and 
electronic cigarettes) for at least 4 hours prior to each study  visit and throughout the duration 
of each study visit.  Study par ticipants may utilize various ni cotine replacement treatments 
such as chewing gum and patches (PRN), in accordance with recom mendations from the 
Investigator during the entire study visit.
Note: Use of electronic cigarettes w ill be viewed and managed in the s ame manner as 
traditional smoking.
5.7 Reasons and Procedures for Early Discontinuation from the 
Study 
5.7.1 Reasons for Discontinuation
Subjects may be withdrawn from the study at any time at their o wn request, upon request of 
the Investigator, or by Pearl at any time or for any reason. A subject who withdraws consent 
will always be asked about the reason(s) and the p resence of an y adverse events (AE).   All 
subjects who discontinue for any  reason, or their family or hea lthcare providers, will be 
contacted 52 weeks post-Randomiza tion to determine vital status , and if appropriate, cause of 
death (Section 8.8) .    The subject may voluntarily disc ontinue treatment at any t ime without 
prejudice to further treatment.  If a subject experiences any o f the changes of concern listed 
below, a repeat assessment s hould be obtained, an d if confirmed , the Investigator or designee 
needs to make a determination a s to the suitability of continui ng the subject in the study.  The 
changes of concern include:
â€¢Calculated QTcF intervals >500 msec, and have increased by 60 mse c or more over test 
day baseline value
â€¢Following dosing, a heart rate i ncrease of >40 bpm from the pre -dose value obtained on 
that specific test day and the measured value is also >120 bpm 
â€¢Following dosing, a systolic bl ood pressure incre ase of >40 mmH g from the 
pre-dose value obtained on that specific test day and the measu red value is also 
>160 mmHg
â€¢'HFUHDVHLQFUHDWLQLQHFOHDUDQFHWRDYDOXHÂ” mL/minute using CKD-EPI formula or a 
clinically relevant change from baseline as determined by the I nvestigator
â€¢Hepatic impairment defined as a bnormal liver function test of A ST, ALT or total 
ELOLUXELQÂ•WLPHVXSSHUOLPLWRI QRUPDORQUHSHDWWHVWLQJ
Confidential and Proprietary Page 39 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
If a subject requires the follo wing prohibited medications, the y should be withdrawn from the 
study:
â€¢Initiation of maintenance therapy  with any prohibited medicatio ns as listed in Section 
5.4.2
â€¢Initiation of maintenance therapy  with a LABA (e.g., salmeterol , formoterol, indacaterol, 
vilanterol, olodaterol)  administered alone  or in combination wi th an ICS or a LAMA 
(e.g., tiotropium, aclidinium, glycopyrronium, umeclidinium) 
â€¢Change inhaled maintenance ther apy during the course of the stu dy 
  
NOTE:  Subjects who suffer an ex acerbation (regardless of sever ity) will remain in the study 
and continue to take their assigned study drug unless the Inves tigator decides that it is in the 
best interest of the subject t o discontinue early from the stud y.  The definition and severity of 
exacerbations are discussed in  Section 7.2.2.1.  If a female subject b ecomes pregnant during 
the course of the study, the  subject will be discontinued and t he pregnancy will be followed 
full-term through delivery or final outcome (see Section 7.2.3.4) .
Confidential and Proprietary Page 40 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
6.3 Primary Packaging and Labeling Information 
Investigational materials will  be packaged by the Sponsor.  Ven tolin HFA will be supplied as
open-label MDIs.
Blinded Supplies : Each MDI will be labeled with a  single label.  The MDI actuat or will be 
labeled with a single label.  T he foil pouch will be labeled wi th a single label. 
Open-label Supplies : Open-label Ventolin HFA will  be provided as i ndividually-labe led 
MDIs.  Each MDI will contain a single label.  The MDI actuator will be labeled with a single 
label. Labels will be printed w ith black ink and may include th e following text: Labels will 
be printed with black ink and may i nclude the following text: 
Lot # (Packaging Lot Trace ID)
Space for entry of screening #Component ID # Space for entry of randomization # Fill Count & Dosage Form Visit # (Space for Entry of Interval ID)Storage Conditions
Protocol # Country regulatory requirements Sponsor address Translation Key 
ID = identification; # = number
Confidential and Proprietary Page 42 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
6.4 Secondary Packaging and Labeling Information (Box) 
Blinded investigational drug a nd open-label supplies (Ventolin HFA) will be packaged in 
individual boxes as outlined in Table 6-2. Box configuration is subj ect to change as a result 
of packaging constraints. 
Table 6-2. Description of Boxes
Drug Supplies Individual Box Contents
Blinded
Ventolin (albuterol sulfate) HFA1 MDI
1 MDI
HFA=Hydrofluoroalkane; M DI=metered dose inhaler
Each box will be labeled with a 2-part label printed with black  ink and may include the 
following text:
Packaging Lot ID #
Space for entry of screening #Component ID # Space for entry of randomization # Kit Contents (1 MDI) Space for entry of Interval IDRe-evaluation/Expirati on date (if applicable)Dosing Instructions (if applicable)
Storage Conditions Compound ID - Protocol #Country regulatory requirements Sponsor address (if applicable) Translation Key (if applicable)
ID = identification; # = number
6.5 Emergency Unblinding of Treatment Assignment  
The IWRS should be used in orde r to unblind subjects and to unm ask drug identity.  When 
the Investigator contacts the  system to unblind a subject, he/s he must provide the requested 
subject identifying informati on and confirm the necessity to un blind the subject.  Pearl will 
not provide a disclosure envelope  with the clinical supplies. 
The Investigator or treating  physician may unblind a subjectâ€™s treatment assignment only in 
the case of an emergency , when knowledge of the study tr eatment is essential for the 
appropriate clinical managemen t or welfare of the subject.
Whenever possible, the Investigat or must first discuss options with the Medical Monitor or 
appropriate study personnel before unblinding the subjectâ€™s treatme nt assignment.  If this is 
impractical, the Investigator mus t notify Pearl as soon as poss ible, but without revealing the 
treatment assignment  of the unblinded subject, unless that info rmation is important for the 
safety of subjects currently i n the study.  The date and reason  for the unblinding must be 
recorded in the appropriat e data collection tool.
Confidential and Proprietary Page 43 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
6.6 Storage Requirements
Blinded Supplies  should be kept in a secured location.  BGF MDI, GFF MDI, and B FF MDI 
should be stored below 25Â° C (77Â°  F) in a dry place.  Excursion s permitted up to 30Â° C (86Â° 
F).
VentolinÂ®HFA supplies: Store between 15Â°C and 25Â°C (59Â°F and 77Â°F).  Store the inhaler  
with the mouthpiece down.  For best  results, the inhaler should  be at room temperature 
before use.  Do not use or store  near heat or open flame.  Expo sure to temperatures above 
120Â°F (49Â°C) may cause bursting . Never throw into a fire or inc inerator. 
The clinical supplies storage ar ea at the site must be monitore d by the site staff for 
temperature consistency with the acceptable storage temperature  range specified in 
accordance with the product labe l.  Documentation of temperatur e monitoring should be 
maintained.
6.7 Instructions for Preparation of Treatments for Administrati on and 
Dispensing 
6.7.1 BGF MDI, GFF MDI, BFF MDI
Individual BGF MDI, GFF MDI, and BFF MDI will be packaged in a foil pouch and 
contained in an individual vis it treatment box.  Both the visit  treatment box and the foil 
overwrap will have a label with a  component ID number.  Confirm  that the identifier given 
by IWRS and the component ID  number written on the label are th e same.  The visit 
treatment box is labe led with a 2-part lab el.  Write the subjec t number and treatment visit 
number on each of the 2-part label s.  The â€˜tear-offâ€™ part of th e label is to be placed onto the 
IWRS confirmation report. 
All MDIs must be primed before t he first use.  Priming involves  releasing a certain number 
of sprays (4) into the air befor e the first use of the inhaler.   Shaking and priming the inhaler 
fills a chamber inside the canister with the correct dose and m ix of medication so that the 
inhaler is ready to use.
The MDI must be primed in a separ ate room, away from the subjec t treatment area.  
Each dose will consist of 2 puffs from the MDI.  Subjects will be dispensed the MDI and 
instructed to continue taking study medication twice daily, 2 p uffs in the morning and 2 puffs 
in the evening appr oximately 12 hours apart, until subject retu rns to the clinic.  The MDI 
should be stored at room tempera ture by the subject, to avoid t emperature extremes, and the 
products should not be stored in di rect sunlight.  Refer to Appendix 2 for instructions on 
administration and cleaning of BGF MDI, GFF MDI, and BFF MDI.   
6.7.2 Ventolin HFAÂ®  
Refer to  Appendix 3 for the manufacturerâ€™s instru ctions on the administration and c leaning of 
Ventolin HFA.
Confidential and Proprietary Page 44 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
6.8 Drug Accountability/Return of Clinical Supplies 
Under no circumstances will the Investigator(s) allow the study  drug to be used other than as 
directed by this protocol. 
Investigational clinical supplies must be received by a designa ted person at the study site, 
handled and stored safely and pr operly, and kept in a secure lo cation to which only the 
Investigator and designated assist ants have access.  Storage co nditions for the clinical 
supplies should be observed, mon itored and documented.  Clinica l supplies are to be 
dispensed only in accordance wit h the protocol.  The Investigat or or designee is responsible 
for keeping accurate records of t he clinical supplies received from Pearl, the amount 
dispensed to and returned by the subject, and the amount remain ing at the conclusion of the 
study. Study medication should be  handled in accordance with Go od Pharmacy Practices 
(i.e., gloves should always be wor n by study personnel if direc tly handling tablets or capsules 
that are returned).  The Clini cal Monitor should be contacted w ith any questions concerning 
investigational products where special or protective handling i s indicated.  At the end of the 
study, all clinical supplies in cluding partial and empty contai ners must be returned as 
directed by Pearl.
Sites should check with the Pearl representative for appropriat e documentation that needs to 
be completed for drug accountability. 
The Investigator or designa ted assistant should not open indivi dual clinical supply containers 
until all pre-dose assessments  have been completed and the subj ect is eligible to be 
randomized/continue with the stu dy.  Any deviation from this mu st be discussed with the 
Clinical Monitor.
For each subject, all used study  drug materials will be collect ed.  Used subject supplies will 
be kept at room temperature in a  secure and locked cabinet unti l returned to Pearl or 
designee.   
Note:  Used study drug will be stored separately from unused study dr ug. 
All product complaints (including  device malfunctions) must be reported to Pearl using the 
Product Complaints Form provide d in each siteâ€™s regulatory bind er.  Pearl will contact the 
site to evaluate the nature of t he complaint and determine what  further action is needed. 
Confidential and Proprietary Page 45 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
7 STUDY PROCEDURES
A schedule of event s is provided in Table 8-1.    
7.1 Bone Mineral Density Assessments 
Bone mineral density will be evalu ated by taking two sets of DE XA scans (lumbar spine and 
hip regions) prior to randomiz ation (Study PT010006 Visit 4) an d Visit 14 (Week 52) in this 
study. After the first scan, of t he lumbar spine and hip region , the subject will get up from the 
table, and be repositioned, to take another set of scans at the se skeletal sites. If these first two 
scans differ by more than 5% (as  determined by the local facili ty) for either site (i.e. first two 
hip or first two lumbar sites)  a third scan should be obtained.  The screening period may be 
extended up to a maximum of 21 days i f additional time is neede d to complete the 
assessments. The results of these  scans will be provided by the central testing facility to the 
investigative site to allow appr opriate management of the subje ct. 
For any clinically relevant re duction in T-score, the investiga tor should consider appropriate 
treatment options based on local g uidelines for the subject and /or refer them to their local 
medical doctor or a specialist fo r treatment. If a subjectâ€™s T- score (hip or lumbar spine) is <-
2.5 at screening they are excluded.
Both the lumbar spine L2-L4 and total hip bone density will be measured. The scans of each 
skeletal site will be centrally  analyzed to obtain the final re sult to be used for data analysis.
For >1 scan the median will be considered for eligibility. 
Full details can be found in the BMD manual 
7.2 Ophthalmologic Assessments
The baseline ophthalmologic asse ssment must be performed prior to Randomization between 
Visits 1 and 4 (Screening) of S tudy PT010006. Two post-baseline  ophthalmologic 
assessments will be performed a t Visit 11 (Week 28), and Visit 14 (Week 52) only per 
exclusion criteri a exception noted in  Section 5.2.2.  These post-baseline ophthalmologic 
assessments should be scheduled t o occur within two weeks prior  to the scheduled clinic 
visit. Due to diurnal variab ility of IOP, all ophthalmic examin ations following the first 
ophthalmic examination (baselin e) should be scheduled to occur within two hours of the time 
of day when the baseline ophthalmic  examination was performed. The same ophthalmologist
should perform the ophthalmic examin ations for a given subject at all visits if possible, to 
ensure consistency.  
At participating centers, all subjects will be referred to a ce rtified as LOCSIII trained 
ophthalmologist/optometrist f or evaluation of  pupil dilation, l enticular opacities, fundoscopic 
examination, intraocular pressure  (IOP), manifest refraction an d visual acuity. This data will 
also be categorized as normal/abnormal. 
The Lens Opacities Classificati on System (LOCS) III grading sys tem will be used to assess 
lenticular opacities in this study. The following assessments w ill be performed using a 
Confidential and Proprietary Page 46 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
decimalized scale ranging from  0.1 (indicating a completely clea r or colorless lens) to either 
5.9 (indicating complete opaci fication on the cortex or posteri or capsule for C or P scales) or 
6.9 (indicating advanced opacifi cation and brunescence of the n ucleus for NO or NC scales). 
Each assessment will be recorde d to the nearest 0.1 as determin ed by the certified 
ophthalmologist/optometrist.Since the posterior subcapsula r region is thought to be the are a most characteristically 
affected by corticosteroid use, t he LOCS III (P) score is the p rimary analysis.
â€¢ Nuclear Opalescence ( NO scale 0.1 to 6.9) is the average of th e opalescence of the
two regions of the nucleus 
â€¢ Nuclear Color (NC scale 0.1 to 6.9)  is the grade of color of the posterior 
   subcapsular reflex (a proxy for nuclear color)  â€¢ Cortical Cataract (C scale  0.1 to 5.9) is the aggregate area of visible opacification (in the 
lightly and darkly shadowed) por tions of the cortical opacities
â€¢ The severity of Posterior Sub capsular Cataract (PSC) will be expressed as a P grade derived
   from the LOCS III P scale (0.1 to 5.9). With a maximally dil ated pupil the LOCS III P  
grade will be defined as the to tal area of aggregated component  PSCs related to the LOCS  
   III P standards, regardless  of where they are located on the  posterior capsule. The method  
for making this assessment will be  dealt with in the LOCS III tr aining recordings.
NOTE: The ophthalmologist/optometri st must not refer to prior L OCS III grades and 
LOGMAR visual acuities from prev ious ophthalmic examination at the time of a new 
examination
Fundoscopic examination will in clude the evaluation of horizont al cup-to-disc ratio for each 
eye.
Intraocular Pressure: Intraocular pressure (IOP) will be measur ed using Goldman 
Applanation Tonometry. Three meas ures of IOP will be completed for each eye during each 
ophthalmic examination and all three measures will be recorded.  The lowest reading will be 
considered to evaluate eligibility criteria
Visual acuity and manifest refraction: 
Visual acuity (best-corrected di stance vision) and manifest ref raction (sphere, cylinder and 
axis) will be assessed during e ach ophthalmic examination. LogM AR (Logarithm of the 
Minimum Angle of Resolution) visual acuity using Early Treatmen t Diabetic Retinopathy 
Study (ETDRS) charts will be utilized. Both the visual acuity a nd manifest refraction values 
will be captured in the source document. 
7.3 Subject Electronic Diary (eDiary) Data Collection
Subjects will continue to use thei r electronic subject diary (e Diary) provided during 
participation in Study PT010006 t o continue to record time of s tudy medication 
administration, use of rescue albuterol (Ventolin HFA), and dos e indicator reading (if 
assigned to BGF MDI, GFF MDI or BFF MDI only). 
Confidential and Proprietary Page 47 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Electronic Diary Compliance Requirement :  Subject participati on may be terminated at 
any time during the study for the following reasons:
â€¢Chronic failure, in the judgment  of the Investigator, to comply  with diary compliance, 
despite documentation at the site  of repeated efforts to reinfo rce compliance.  As defined 
for this study, compliance requi res >70% subject completion of diary assessments.  Pearl 
may also instruct a site t o discontinue a subject based on cons istent noncompliance   
In-clinic dosing times and dose i ndicator readings will be docu mented by the site staff and 
will not be entered by the subject into their eDiary.
The eDiary data report will be  available to site personnel thro ugh the vendor's server. The 
eDiary data report should be rev iewed by the study personnel at  each visit. The review 
should verify that morning and evening diary entries have been recorded by the subject for 
compliance requirements.  The  subject should be reinstructed, a s appropriate, on the 
importance of recording twice dail y entries if missing entries are observed.
7.3.1 Rescue Medication Usage
The subject will record the total  number of â€œpuffsâ€ of rescue m edication (i.e., albuterol 
sulfate or locally available equivalent produ ct) used on a dail y basis in the eDiary.  The 
number of â€œpuffsâ€ of rescue pr oduct will be recorded as the num ber of actuations on the 
canister.  For example, when r escue product is required and 2 a ctuations are inhaled, this 
should be recorded as 2 â€œpuffs.â€  In the event the subject requ ires 4 actuations, this should be 
recorded as 4 â€œpuffsâ€.  Subject s requiring more than 8 puffs pe r day on 3 consecutive days 
with worsening symptom s should contact the site.   
7.3.2 Medication Compliance 
Time of dosing with study medic ation will be recorded in the su bjectâ€™s eDiary for each day 
of treatment (except the in-c linic dosing time).  Study medicat ion compliance will be 
checked at all visits, and any i ssues identified will be docume nted in the appropriate study 
files.
7.3.3 Recording of Dose Indicator Reading
The BGF MDI, GFF MDI and BFF MDI will be fitted with a dose indi cator to track in life 
use of the MDI.
Subjects will be instructed to r ecord the dose indicator readin g from the MDI in their 
eDiary.
Prior to dosing at Visit 11 t o Visit 14, site personnel will ob serve the dose indicator reading 
on the study drug returned by the subject and record the dose i ndicator reading in the source.
Confidential and Proprietary Page 48 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Note: The dose indicator reading recorded by the site staff will be d ose indicator reading 
observed prior to subject dosing.  For new MDIs the recorded co unt will be the count
following the priming of the MDI but before the subject dose. 
At each visit, the site staff will compare the dose indicator r eading from the prior evening 
entered in the subject eDiary w ith the dose indicator reading r ecorded by the site staff.  For 
major discrepancies (i.e., >20 pu ff difference) the site staff w ill review the major discrepancy 
with the subject and document reas on for the major discrepancy.   If appropriate, site staff 
will retrain the subject on the proper recording of dose indica tor reading and/or proper use of 
the MDI.
7.3.4 Major/minor Symptom Worsening Assessment and Alert System
All major and minor symptoms of  a worsening event will be captu red at once each morning 
for the purposes of a symptom worsening alert. The purpose of t his alert is to notify both the 
subject and the site of a potential symptom worsening event tha t warrants contact between 
the subject and site for  further evaluation. 
All questions will ha ve a 24-hour recall pe riod.  Questions per taining to the severity of 
symptoms versus their usual st ate will have 3 response options (e.g., How breathless have 
you been in the last 24 hours? Les s breathlessness than usual, Usual level of breathlessness, 
More breathless than usual) whe reas questions related to the pr esence or absence of a
symptom will have a dichotomous  response (e.g., Have you had a sore throat in the last 24 
hours? No, Yes, I had a sore throat). 
An alert will be triggered if 2 or  more major symptoms (dyspnea , sputum volume, and 
sputum color) worsen for 2 consecu tive days or if 1 major sympt om and 1 minor symptom 
(sore throat, cold, fever wit hout other cause, cough, and wheez e) worsen for at least 
2 consecutive days. When either of these criteria is met, the su bject will be ale rted via the 
eDiary to contact the site as s oon as possible for further eval uation. Likewise, the study site 
will be alerted to contact the subject within approximately 24 to 72 hours if he/she has not 
yet contacted the study sit e for further evaluation.
7.3.5: EXACT
The exacerbations of chronic pulm onary disease tool (EXACT) que stionnaire will be 
captured via the subject eDiary (see Appendix 4)
7.4 COPD Exacerbations 
A COPD exacerbation will be defined a s a change in the subjectâ€™s  usual COPD symptoms 
that lasts 2 or more days, is beyond normal day-to-day variatio n, is acute in onset, and may 
warrant a change in regular med ication.  The change in symptoms  must include at least one 
major COPD symptom and at least  one other major or minor sympto m from the list below:
xMajor COPD symptoms: dyspnea , sputum volume, and sputum color  
Confidential and Proprietary Page 49 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
xMinor COPD symptoms: cough, wheez e, sore throat, cold symptoms (rhinorrhea or nasal 
congestion), and fever w ithout other cause   
If symptoms are acute or have progressed rapidly and require tr eatment less than two days 
from onset of symptoms, the inve stigator will have to justify t he decision for defining the 
event as an exacerbation and record it in the eCRF. 
If a subjectâ€™s symptoms and the  overall clinical findings suppo rt the diagnosis of a COPD 
exacerbation, but the subject has not  experienced a worsening o f at least one major COPD 
symptom and at least one other major or minor symptom, the inve stigator will have to justify 
the decision for defining the e vent as an exacerbation and reco rd it in the eCRF. 
7.4.1 Severity of COPD Exacerbation
COPD exacerbations will  be classified as mild, moderate or seve re based on the following 
criteria:
Exacerbations will be considered m oderate if they result in: 
xUse of systemic corticosteroids and/or antibiotics for at least  3 days; a single depot 
injectable dose of corticosteroid s will be consid ered equivalen t to a 3-day course of 
systemic corticosteroids
Exacerbations will be considere d severe if they result in: 
xAn inpatient COPD-related hosp italization (docum entation statin g that the subject was 
KRVSLWDOL]HGIRUWKH&23'H[DFHU EDWLRQRUDUHFRUGRIWKHVXEMH FWEHLQJDGPLWWHGIRUÂ•
hours to  an observation area, the  emergency department, or oth er equivalent healthcare 
facility depending on the count ry and healthcare system) 
xCOPD-related death
Exacerbations will be considered mild if they do not meet the r equirements to be  classified as 
moderate or severe but otherwis e fulfill the definition of COPD  exacerbation.  
7.4.2 Duration of COPD exacerbation
For moderate or severe exacerba tions, the duration is defined b y the length of prescribed 
treatment, whereas for mild ex acerbations, the duration is defi ned by the length of symptoms. 
For moderate or severe COPD e xacerbations, the  start date will be defined as the start date of 
prescribed treatment with a systemic corticosteroid or systemic  antibiotic and the stop date 
will be defined as the last day of  prescribed treatment with a systemic corticosteroid or 
systemic antibiotic.  In order t o ensure that the same event is  not counted twice, concurrent 
moderate or severe COPD exacer bations with sta rt and stop dates  equal to or less than 7 days 
apart will be considered the sam e event and assigned the maximu m severity between the 
two.
Confidential and Proprietary Page 50 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
For mild COPD exacerbations, sta rt date will be de fined as the onset of worsened symptoms 
as recorded by the subject in t he eDiary, and the stop date wil l be defined as the last day of 
worsened symptoms.  In order to e nsure that the same event is n ot counted twice, mild COPD 
exacerbations with start and stop da tes equal to or less than 7  days apart will be considered 
the same event.   
7.4.3 Approach for Capturing COPD Exacerbations
All moderate or severe COPD ex acerbations must be captured usin g the COPD Exacerbation 
eCRF.  Mild COPD exacerbations w ill be captured based on sympto ms as recorded by the 
subject in the eDiary.  COPD ex acerbations of any severity will  be considered expected study 
endpoints and will not be  reported as adverse events (AEs) unle ss considered a serious AE 
(SAE).
7.4.4 Other Information
Pearl Therapeutics will be using an electronic diary (eDiary) t o capture daily symptom 
reporting.  If symptoms meet a s pecific threshold (i.e., one ma jor COPD symptom and at 
least one other major or minor s ymptom for 2 consecutive days),  the eDiary generates alerts 
to the subject and the clinical s ite.  This alert is intended t o generate a contact between the 
subject and the clinical investig ator.  The clinical investigat or makes the decision to escalate 
or initiate treatment  (steroids and/or an tibiotics and/or hospi talizations).
Circumstances will occur where symptoms are not captured in the  eDiary (e.g., technical 
difficulties, rapid deteriora tion, or sudden death).  In these cases, the investig ator or designee 
will enter the information into the eCRF to capture the symptom s related to a COPD 
exacerbation.
7.4.5 Investigator-Judged COPD Exacerbations
For events which do not meet the ou tlined symptom criteria and/ or when symptoms have a 
shorter duration, the investigat or can justify the decision for  considering the event an 
exacerbation.  Exacerbations could be  defined by an investigato r when symptoms of COPD 
warranted urgent treatment due t o rapid onset or rapidly progre ssive symptoms.  Such a 
situation does not allow en RXJKWLPHWRVWULFWO\IXOILOOWKH FULWHULDIRUV\PSWRPGXUDWLRQ Â•
consecutive days).  In these cases, the investigator may define  such an event as a COPD 
exacerbation.  As clinical presen tations may vary among patient s with COPD, exacerbations 
defined by an investigator can be  supported by respiratory symp toms that may not strictly 
fulfill all symptom requirement s defined above.  Since the inve stigator will need to document 
the symptoms that justify his  or her decision to begin treatmen t defining a COPD 
exacerbation event, all exacerbati ons in the study will have do cumented symptoms justifying 
their clinical relevance.  
7.5 Subject Questionnaire
The exacerbations of chronic pulm onary disease tool (EXACT) que stionnaire will be 
captured via the subject eDiary (see Appendix 4 ).
Confidential and Proprietary Page 51 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
7.6 Safety Assessments
The safety assessments include ph ysical examination findings, v ital signs, ECGs, and clinical 
laboratory tests in addition to r ecording of AEs and SAEs.  
7.6.1 Medical/Surgical History and Physical Examination
Medical history, including speci fic cardiovascular history deta ils, will be collected at Visit 1 
(Screening) in Study PT010006. A com plete physical examination will be performed at the 
conclusion of Study PT010006 (Vis it 10a) and will not be obtain ed during Visit 10b. A 
complete physical examination w ill also be conducted at the Fin al Visit (Visit 14) or at the 
Treatment Discontinua tion/Withdrawal Visit, if applicable. A co mplete physical examination 
will include evaluati on of the following: general appearance, s kin, head, eyes, ears, nose, 
throat, neck (including thyroid), lymph nodes, chest, heart, ab domen, extremities, and 
nervous system. Weight, assesse d in ordinary indoor clothing wi th shoes removed will be 
recorded in Study PT010006 at Visit 1 and Visit 10a only. Heigh t will be recorded at Visit 1 
(PT010006 Screening) only.
7.6.2 Vital Sign Measurements
Vital signs, including heart r ate (HR) and systolic and diastol ic blood pressure (DBP), and 
temperature will be assessed as  outlined below; assessments may  be obtained while the 
subject is resting for 5 minut es in either the supine or seated  position. 
Vital signs will be obtained at the conclusion of the lead-in s tudy PT010006 (Visit 10a) and 
will not be obtained during Visit 10b. 
At Visits 11 through 13:  
â€¢Pre-dose vital signs will be  obtained once within 60 minutes pr ior to study drug dosing 
â€¢Post-dose vital signs will be  obtained at 30 minutes post study  drug dosing 
A single set of vital signs w ill also be obtained at a Visit 14  (Week 52) or at the Treatment 
Discontinuation/Withdrawal  Visit, if applicable.
Temperature will be obtained pr e-dose at all visits and will no t be repeated at subsequent 
time points unless clinically indi cated. A single set of vital s igns will be obtained at the 
Treatment Discontinua tion/Withdrawal Visit, if applicable. 
7.6.3 12-Lead Electrocardiogram 
ECGs will be obtained at the c onclusion of Study PT010006 (Visi t 10a) and will not be 
obtained during Visit 10b. 
At Visit 12 (Week 36) only, an E CG will be obtained within 60 m inutes prior to study drug 
dosing. 
Confidential and Proprietary Page 52 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
7.6.4.1 Hematology
Hemoglobin, hematocrit, red bl ood cell count, white blood cell count with differential, and 
platelet count will be measured pr ior to dosing at the final vi sit of Study PT010006 (Visit 
10a), and will not be obtai ned during Visit 10b.   
Hematology assessments will be obt ained prior to dosing at Visi t 12 (Week 36). Hematology 
assessments will also be obtai ned and Visit 14 (Week 52) or at the Treatment 
Discontinuation/Withdrawal  Visit, if applicable.
7.6.4.2 Clinical Chemistry
Albumin, alkaline phos phatase, blood urea nitr ogen (BUN), total  bilirubin, calcium, total 
cholesterol, magnesium, phospha te, sodium, potassium, chloride,  creatinine, Ë -GT, blood 
glucose, total protein, bicar bonate, triglycerides, AST and ALT  will be measured prior to 
dosing at the final visit of S tudy PT010006 (Visit 10a), and wi ll not be obtained during Visit 
10b.
Clinical chemistry assessments  will be obtained at Visit 12 (We ek 36). Hematology 
assessments will also be obtai ned and Visit 14 (Week 52) or at the Treatment 
Discontinuation/Withdrawal  Visit, if applicable.
Refer to  Table 7-1 for a list of study-associated l aboratory tests.  The central l aboratory will 
supply procedures for the prep aration and colle ction of these s amples. 
Confidential and Proprietary Page 54 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Table 7-1. Clinical Laboratory Tests
Hematology
Hemoglobin Mean corpuscular 
hemoglobin 
Hematocrit Mean corpuscular hemoglobin 
concentration 
White blood cell count with differential Mean corpuscular volum e 
Red blood cell count Eosinophils
Platelet count 
Clinical Blood Chemistry
Liver Enzyme and Other Liver Func tion Tests Other Clinical Blood
Chemistry
Alanine aminotransferase Albumin
Aspartate aminotransferase Blood Urea Nitrogen (BUN)
Alkaline phosphatase Calciuma
Bilirubin, total Chloridea
Gamma-glutamyl transferase Cholesterol 
Bicarbonate
Creatininea
Glucosea
Magnesium 
Potassiuma
Phosphate
Protein, total 
Sodiuma
Urinalysis
Macroscopic examination includin g specific gravity, pH, protein , glucose, ketones, blood, and 
urobilinogen.
Other Tests:
Pregnancy test (women of childbearing potential only):  serum h CG at Visit 10a of Study PT010006  and  at Visit 14
(Week 52) the Treatment Disconti nuation/Withdrawal Visit of this  study.
Creatinine clearance will be estimated by the CKD-EPI formula [Levey, 2009 ].
Abbreviations: CKD-EPI=Chronic Ki dney Disease Epidemiology Coll aboration; hCG=human chorionic 
gonadotropin
aParameters included in the Basic Metabolic Panel.
7.6.4.3 Urinalysis
Urinalysis will be measured at th e final visit of Study PT01000 6 (Visit 10a), and will not be 
obtained during Visit 10b.  
Urinalysis will be obtained prior to dosing at Visit 12 (Week 3 6).  Urinalysis will be obtained 
at Visit 14 (Week 52) or at the Tr eatment Discontinuation/Withd rawal Visit, if applicable.
7.6.4.4 Pregnancy Test
A serum pregnancy test will be pe rformed at the Central Laborat ory in pre-menopausal 
women who are not surgically sterile  at the final visit of Stud y PT010006 (Visit 10a), and 
will not be obtained during Visit 10b.   
A serum pregnancy test will al so be obtained at Visit 14 (Week 52) or at the Treatment 
Discontinuation/Withdrawal  Visit, if applicable. 
Confidential and Proprietary Page 55 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
A urine pregnancy test will be  performed at Visit 12 (Week 36).    
If any of these tests are positive, the subject must be discont inued from the study.  The 
pregnancy test should be performe d prior to ECG or blood collec tion for laboratory 
assessments.
7.7 Adverse Events
7.7.1 Performing Adverse Events Assessments
The Investigator is responsible  for promptly documenting and re porting all AEs observed 
during the study in the subject â€™s case report form and on the A E Reporting Form. If the AE is 
â€œalarming,â€ the Investigator must report the AE immediately to Pearl.  In addition, certain 
AEs (as described in  Section 7.4.9)  are classified as "serious" and must be reported no later 
than 24 hours after the Investigat or recognizes/classifies the event as an SAE to Pearl or its 
designee.
In the case of SAEs, after disc ussing the details of the AE, th e Investigator and the Medical 
Monitor may discontinue the subject prematurely. 
7.7.2 Adverse Event Definitions
The following definitions of terms  are guided by the Internatio nal Conference on 
Harmonisation of Technical Require ments for Registration of Pha rmaceuticals for Human 
Use (ICH), the US Code of Fed eral Regulations (21 CFR 312.32) a nd EU Directive 
2001/83/EC and are i ncluded herein. 
An AE is any untoward medical o ccurrence associated with the us e of a drug in humans, 
whether or not considered drug r elated.  An AE (also referred t o as an adverse experience) 
can be any unfavorable and uninte nded sign (e.g., an abnormal l aboratory finding), symptom, 
or disease temporally associate d with the use of a drug, withou t any judgment about 
causality.  An AE can arise from any use of the drug (e.g., off -label use, use in combination 
with another drug) and from any route of adminis tration, formul ation, or dose, including an 
overdose. 
Adverse events include , but are not limited to: 
â€¢ Any symptom or condition not previously reported by the subjec t (medical history) 
â€¢ An exacerbation of a pre-existing symptom or conditionâ€¢ A significant increase in fre quency or intensity of a pre-exi sting episodic event or 
condition 
â€¢ A drug interactionâ€¢ A condition first detected or di agnosed after study drug admi nistration even though it 
may have been present prior to the start of the study 
Confidential and Proprietary Page 56 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
An AE does not include: 
â€¢ Medical or surgical procedures (e.g., surgery, endoscopy, too th extraction, blood 
transfusion); the condition that leads to the procedure are an AE (e.g., bleeding 
esophageal varices, dental caries)
â€¢ Overdose of either study drug or concurrent medication withou t any clinical signs or 
symptoms
â€¢ Non-clinically significant abnormal laboratory values.  (If ac companied by 
signs/symptoms, the signs or symptoms are considered an AE.) 
7.7.3 Severity
The Investigator must categoriz e the severity of each AE accord ing to the following 
guidelines: 
Mild : Associated with no limitation of us ual activities or only sli ght discomfort; generally not 
requiring alteration or  cessation of study dr ug administration;  and/or not needing therapeutic 
intervention. 
Moderate : Associated with limitation of us ual activities or significant  discomfort; generally 
requiring alteration or  cessation of study dr ug administration;  and/or requiring  therapeutic 
intervention. 
Severe : Associated with inability of subject to carry out usual activ ities or very marked 
discomfort; considered to be lif e-threatening; resulting in sig nificant disability or incapacity; 
and requiring therape utic intervention. 
7.7.4 Relationship
The relationship of each AE to the  study drug administration wi ll be assessed by the 
Investigator after careful cons ideration, and according to the following guidelines: 
Definitely : A reaction that follows a reason able temporal sequence from a dministration of 
study drug; that follows a know n or expected response pattern t o the study drug; it disappears 
or decreases on cessation or reduction in study drug dose; and/ or it reappears or worsens 
when the study drug is administered. 
Probably : A reaction that follows a reason able temporal sequence from a dministration of 
study drug; that follows a know n or expected response pattern t o the study drug; and/or that 
could not be reasonably explaine d by other factors such as unde rlying disease, complications, 
concomitant drugs, or con current treatments. 
Possibly:  A reaction that follows a reason able temporal sequence from ad ministration of 
study drug; that follows a know n or expected response pattern t o the study drug, but that 
could reasonably have been produ ced by a number of other factor s including underlying 
disease, complications, concomita nt drugs, or concurrent treatm ents. 
Confidential and Proprietary Page 57 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Not Related : A reaction for which sufficien t data exist to indicate that t he etiology is 
unrelated to the study drug. 
7.7.5 Chronic Obstructive Pulmonary Disease Exacerbations
All moderate or severe COPD ex acerbations must be captured usin g the COPD Exacerbation 
eCRF.  Mild COPD exacerbations w ill be captured based on sympto ms as recorded by the 
subject in the eDiary.  COPD ex acerbations of any severity will  be considered expected study 
endpoints and will not be  reported as adverse events (AEs) unle ss considered a serious AE 
(SAE). 
Exacerbation(s) of COPD is exp ected to occur as a progression o f disease despite 
standardized drug tre atment, or treatment(s ) with combination t herapies. As a result, the 
Sponsor has classified this even t as a protocol specified crite ria expected event. Any 
individual case safety reports received related to exacerbation  of COPD will not be submitted 
on an expedited basis as a Suspect ed Unexpected Serious Adverse  Reaction (SUSAR) unless 
otherwise required as per the Sponsorâ€™s medical assessment.
7.7.6 Adverse Events of Special Interest
Certain AEs have been identified a s adverse events of special in terest (AESIs) due to the 
class of drugs being studied.  A dditional adverse events of spe cial interest , including 
increased IOP, glaucoma, other oc ular AEâ€™s and fractures will b e defined in the SAP. Some 
events are described below but thi s is not a comprehensive list  of all AESIs.
7.7.6.1 LABA and LAMA Effects
Known effects of LAMAs and LABAs include cardiovascular effects , ocular disorders, 
urinary retention, gastrointes tinal disorders, and anticholiner gic effects for LAMAs and 
cardiovascular and tremor effects for LABAs. 
7.7.6.2 Local Steroid Effects 
Local steroid effects include or al candidiasis, hoarseness cand idiasis, oropharyngeal 
candidiasis, dysphonia, and throat irritation.  
7.7.6.3 Pneumonia
In order to adequately assess a nd characterize the risk of pneu monia in patients in a non-
biased manner, an external, i ndependent pneumon ia adjudication committee (PAC) will 
review all adverse events repor ted as pneumonia to ensure appro priate pre-defined and 
clinically consistent pne umonia criteria are met.
To standardize the diagnosis of  pneumonia a clinically consiste nt definition of pneumonia 
will be implemente d, which will require the following: 
1. Clinical diagnosis of pneum onia by the investigator 
Confidential and Proprietary Page 58 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
2. Documentation of chest imagi ng obtained within 14 days of the  diagnosis of pneumonia 
that is compatible wit h the diagnosis of pneumonia 
3. Treatment with antibiotics (and/ or if appropriate antiviral a nd/or antifungal agents)
4. At least 2 of the following clin ical signs, symptoms, or labo ratory findings: 
â€¢Increased cough  
â€¢Increased sputum purulence or production  
â€¢Adventitious breath sounds on auscultation  
â€¢Dyspnea or tachypnea 
â€¢Fever
â€¢Elevated white blood cell counts 
â€¢Hypoxemia 
The PAC will be empowered to re quest any additional information , including copies of chest 
X-rays or CT scans if needed, to c onfirm the pneumonia diagnosi s.   
Radiographs will be evaluated lo cally and the results (infiltra te compatible with pneumonia 
(yes/no) will be entered in the  eCRF.  If the investigator beco mes aware that a diagnosis of 
pneumonia was made without a che st image having been performed,  he or she should obtain 
a chest image (frontal and l ateral) up to 10 to 14 days after t he date of pneumonia diagnosis.  
7.7.6.4 Paradoxical Bronchospasm
Monitoring for paradoxical br onchospasm will occur through spon taneous reporting. 
7.7.7 Major Adverse Cardiovascular Events (MACE)
Due to the prevalence of cardi ovascular diseases in patients wi th COPD, MACE will be 
evaluated according to pre-defined criteria as described in the  Charters.  CCV and Mortality 
Adjudication Committees will review  and adjudicate serious CCV events as MACE and are 
defined as the following: 
xCardiovascular death
xNon-fatal myocardial infarction (MI)
xNon-fatal stroke
Charters will be established to g overn these processes prior to  the First Patient First Visit.  
7.7.8 Clinical Laboratory Adverse Events
Many laboratory abnormalities obs erved during the course of a s tudy will be included under 
a reported AE describing a clini cal syndrome (e.g., elevated BU N and creatinine in the 
setting of an AE of renal failu re, or decreased hemoglobin in a  case of bleeding esophageal 
varices).  Isolated laborator y abnormalities s hould be reported  as AEs if they are considered 
to be clinically significant by the Investigator.
Confidential and Proprietary Page 59 of 112 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Criteria for a "clinically significant" laboratory abnormality are:
â€¢ A laboratory abnormality th at leads to a dose-limiting toxici ty (e.g., an abnormality that 
results in study drug dose reduc tion, suspension, or discontinu ation) 
â€¢ A laboratory abnormality that r esults in any therapeutic inter vention (i.e., concomitant 
medication or therapy)
â€¢ Other laboratory abnormality ju dged by the Investigator to be of any particular clinical 
concern (e.g., significant fa ll in hemoglobin not requiring tra nsfusion) 
For laboratory abnormalities that do not meet the above criteri a but are outside of normal 
range (e.g., < or > normal refere nce range), the Investigator s hould indicate whether the 
value is clinically significant  or not clinically significant f or the subject.
7.7.9 Serious Adverse Events
An AE is considered â€œseriousâ€ if, in the view of the Investigat or or Sponsor, it results in any 
of the following outcomes: 
â€¢Death
â€¢A life-threatening AE
â€¢In patient hospitalization or pr olongation of existing hospital ization  
â€¢A persistent or significant in capacity or substantial disruptio n of the ability to conduct 
normal life functions 
â€¢A congenital anomaly/birth defect
Important medical events that m ay not result in death, be life threatening, or require 
hospitalization may be consider ed serious when, based upon appr opriate judgment, they may 
jeopardize the subject or subject  and may require medical or su rgical intervention to prevent 
one of the outcomes listed in the  definition.  Examples of such  medical events include 
allergic bronchospasm  requiring intensive  treatment in an emerg ency room or at home, blood 
dyscrasias or convulsions that  do not result in subject hospita lization, or the de velopment of 
drug dependency or drug abuse. 
Hospitalization for a pre-existin g condition, including electiv e procedures, which has not 
worsened, does not constitute an SAE. 
An AE or suspected adverse reac tion is considered â€œlife-threate ningâ€™ if, in the view of the 
Investigator or Sponsor, its occu rrence places the subject or s ubject at immediate risk of 
death.  It does not include an adv erse reaction or suspected ad verse reaction that, had it 
occurred in a more severe for m, might have caused death. 
An AE or suspected adverse reac tion is considered unexpected if  it is not listed in the current 
Investigator brochure or is not listed at the specificity or se verity that has been observed.  
Confidential and Proprietary Page 60 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
7.7.9.1 Reporting of Serious Adverse Events
In agreeing to the provisions of t his protocol, the Investigato r accepts all legal responsibilities 
for AE identification, documenta tion, grading, assignment of ca usality, and prompt 
notification of SAEs to Pearl Ph armacovigilance or designee.  A ll SAEs must be reported to 
Pearl Therapeutics no later tha n 24 hours after the Investigato r recognizes/classifies the event 
as an SAE.  At a minimum, a descri ption of the event and the In vestigatorâ€™s judgment of 
causality must be provided at the time of the initial report us ing the appropriate form (e.g., 
SAE Report Form).  After the in itial report, as necessary, the Investigator must provide any 
additional information on a SAE t o Pearl Pharmacovigilance with in 2 working days after 
he/she receives that informa tion.  This follow-up information w ill be a detailed written report 
that may include copies of hosp ital records, case reports, and autopsy reports, and other 
pertinent documents. 
Post-study SAEs following the last dose of study drug must be r eported to Pearl as described 
inSection 7.4.9.4.
The Investigator is responsible  for continuing to report any ne w or relevant follow-up 
information that he/she  learns about the SAE. 
7.7.9.2 Supplemental Investigations of SAEs
The Investigator and supporting pe rsonnel responsible for subje ct care should discuss with 
the Medical Monitor any need for  supplemental investigations of  SAEs.  The results of these 
additional assessmen ts conducted must be r eported to Pearl.  If  a subject dies during 
participation in the study and a  post-mortem examination is per formed, a copy of the autopsy 
report must be submitted to Pearl.
7.7.9.3 Post-Study Follow-Up of Adverse Events
Any AEs that are unresolved at th e subjectâ€™s last AE assessment  in the study are followed up 
by the Investigator for as long  as medically indicated, but wit hout further recording in the 
eCRF.  Pearl retains the right t o request additional informatio n for any subject with ongoing 
AE(s)/SAE(s) at the end of the  study, if judged necessary. 
7.7.9.4 Notification of Post-Study Serious Adverse Events
Investigators are not obligated t o actively follow subjects aft er the completion of the study.  
However, if the Investigator beco mes aware of a post-study SAEs  occurring up to 14 days 
following the last dose of study  drug must be reported to Pearl , whether or not  the event is 
attributable to study drug.  All SAEs must be reported to Pearl  no later than 24 hours after the 
Investigator recognizes/clas sifies the event as an SAE.
7.7.9.5 Investigational Research Board/Independent Ethics Commit tee Notification of 
Serious Adverse Events
The Investigator is responsible  for promptly notifying her/his Investigational Research 
Board/Independent Ethics Committee (IRB/IEC) of all SAEs, inclu ding any follow-up 
Confidential and Proprietary Page 61 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
information, occurring at her/his site and any SAE regulatory r eport, including any follow-up 
reports that he/she receives fro m Pearl.  Documentation of the submission to the IRB/IEC 
must be retained for each safety  report.  The Investigator is a lso responsible for notifying 
Pearl if their IRB/IEC require s revisions to the ICF or other m easures based on its review of 
an SAE report. 
7.7.9.6 Health Authority Safety Reports
Pearl or its representatives will submit a safety report to the  Food and Drug Administration 
(FDA) and/or any other appropria te regulatory agencies, for any  suspected adverse reaction 
that is both serious and unexpecte d within the app ropriate time  frame. 
Pearl or its representatives  will send copies of each safety re port submitted to the FDA and/or 
other regulatory agencies to the Investigators who are actively  participating in Pearl-
sponsored clinical studies.  Saf ety reports must be submitted t o the appropriate  IRB/IEC as 
soon as possible.  Documentati on of the submission to the IRB/I EC must be retained for each 
safety report.
7.7.10 Overdose
An overdose is defined as a dose greater than the high dose lev el evaluated in this study as 
described in Section 6.2 (Product Descriptions) that res ults in clinical signs and sympt oms.  
In the event of an overdose of s tudy medication, the Investigat or should use clinical 
judgment in treating the overdos e and contact the study Medical  Monitor. The Investigator 
should refer to the relevant docum ent(s) for det ailed informati on regarding warnings, 
precautions, contraindications, A Es, and other significant data  pertaining to the study drug(s) 
being used in this study. Such document may include, but not be  limited to, the Investigatorâ€™s 
Brochure for BGF MDI, BFF MDI, GFF MDI, and approved product labe ling for open-label 
products. 
7.7.11 Pregnancy
To ensure subject safety, each pr egnancy in a female subject fr om Visit 1 (Screening) until 
study completion must be re ported to Pearl within 24 hours of l earning of its occurrence.  
The pregnancy should be follo wed up to determine  outcome, inclu ding spontaneous or 
voluntary termination, details of  the birth, and the presence o r absence of any birth defects, 
congenital abnor malities, or maternal and/ or newborn complicati ons.  Pregnancy should be 
recorded on a Paper Pregnancy Re port Form and reported by the I nvestigator to Pearl 
Pharmacovigilance or designee .  Pregnancy follow-up should be r ecorded on the same form 
and should include an a ssessment of the possible relationship t o the Pearl study drug of any 
pregnancy outcome.  Any SAE exper ienced during pregnancy must b e reported on the SAE 
Report Form. 
7.7.12 Use of Steroids during the Study
At each visit, subjects will be ask ed whether they have been ad ministered oral, intramuscular, 
or intravenous corticos teroids since last visit.  Use of oral, intramuscular, or intravenous 
corticosteroids for the management of COPD exacerbations or oth er condition is not a reason 
Confidential and Proprietary Page 62 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
for early termination.  Use of c orticosteroids should be docume nted.  Subjects who are being 
treated for a COPD exacerbatio n with oral corticosteroids or ha ve been treated for a COPD 
exacerbation with oral corticoste roids within 14 days of the sc heduled visit w ill be allowed to 
perform PFTs under close medi cal supervision.  The Investigator  can decide to stop PFTs if 
subject safety is at risk or sym ptoms make it difficult for the  subject to continue.
Subjects treated wit h oral, intramuscular , or intravenous corti costeroids for other indications 
will follow their visit schedule.  If a subject requires intrao cular corticosteroids, this should 
be fully documented and the Inve stigator should make a determin ation as to the suitability of 
the subject continuing in the study. 
7.7.13 Clinical Endpoint Committee 
An external clinical endpoint committee (CEC) that was initiate d in Study PT010006 will 
continue to provide s ystematic and unbiased a ssessment of pre-d efined, Investigator reported 
adverse events for Study P T010008.  The committee will consist of experts who will provide 
a centralized review functioning  independently of Pearl. Three Clinical Endpoint 
Adjudication Charters will outlin e the clinical endpoints for a djudication.   
â€¢Cardiovascular and Cerebrovascul ar (CCV) Clinical Endpoint Adju dication Charter
â€¢Cause-Specific Mortality Clini cal Endpoint Adjudication Charter
â€¢Pneumonia Clinical Endpoi nt Adjudication Charter 
7.7.13.1 Cardiovascular and Cerebrovascular (CCV) Clinical Endpoi nt Adjudication 
Charter
A Cardiovascular and Cerebrovasc ular (CCV) Clinical Endpoint Ad judication Charter will 
be referenced for the review an d assessment of non-fatal seriou s CCV events and 
classification of Major Adverse Ca rdiovascular Event (MACE).  T he CEC will review 
potential clinical endpoints to det ermine if the event meets MACE  criteria.  
7.7.13.2 Cause-Specific Mortality Clinical Endpoint Adjudication Charter
A Cause-Specific Mortality C linical Endpoint Adjudication Chart er will be referenced for the 
review and assessment of the cause of deaths. The CEC will revi ew fatal reports to determine 
if the event meets MACE criteri a. Cardiovascular deaths will be  classified as MACE.    
7.7.13.3 Pneumonia Clinical Endpoint Adjudication Charter
A Pneumonia Clinical Endpoint A djudication Charter will be refe renced for the review and 
assessment of all pneum onia-related events t o ensure appropriat e pre-defined and clinically 
consistent pneumonia criteria are met. 
7.7.14 Data Monitoring Committee
An external Data Monitoring Committee (DMC) that was initiated in Study PT010006 will 
continue to provide s ystematic and unbiased assessment of safet y for Study PT010008.  
Confidential and Proprietary Page 63 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
Members of the DMC will review da ta at predetermined intervals.   If significant safety issues 
arise in between scheduled mee tings, ad hoc meetings will be sc heduled to review the data. 
Based on the safety implications of  the data, the DMC may recom mend modification or 
termination of the study. 
7.8 Termination of the Study
An Investigator may choose to di scontinue study participation a t any time with sufficient 
notice by the Investigator for any reason as per the terms of t he contract with Pearl.  
Pearl reserves the right to discontinue the study at any time f or clinical or administrative 
reasons.  Such a termination must be  implemented by the Investi gator, if instructed to do so 
by Pearl, in a time frame that is compatible with the subjectsâ€™  wellbeing.
Confidential and Proprietary Page 64 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Trial Protocol:  PT010008-01 Version 2.0,
8 STUDY ACTIVITIES
A schedule of event s is provided in Table 8-1.
Confidential and Proprietary Page 65 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
8.1 Baseline Assessments
The Baseline PT010008 Assessments  will be conducte d concurrentl y with PT010006 
Screening.  If the first two B MD scans differ by more than 5% ( as determined by the local 
facility) for either s ite (i.e. first two hi p or first two lumba r sites) a third scan should be 
obtained. The screening period m ay be extended up to a maximum of 21 days if additional 
time is needed to complete the assessments All study assessments  are to be completed prior 
to Randomization (Visit 4) in PT010006. 
â€¢Obtain informed consent prio r to conducting any Study PT010008 baseline assessments. 
â€¢Register subject in IWRS for Study PT010008 at the same time re gistering in Study 
PT010006.  
â€¢Conduct BMD assessments (Refer to Section 7.1)
â€¢Conduct ocular asse ssments (Refer to  Section 7.2)
8.2 Randomization  
â€¢Review Study PT010008 inclusion/ex clusion criteria and confirm subjectâ€™s eligibility to 
continue. 
â€¢Obtain subject randomization numbe r and treatment assignment in formation from IWRS.  
Note :  Randomization in PT01008 o ccurs simultaneously with ran domization in Study 
PT010006 for those patients w ho qualify for Study PT010008. 
â€¢A reminder phone contact shoul d be made prior to Visit 10b. 
8.3 Visit 10b  
The last visit of the Study  PT010006 and the fir st post-baselin e visit of Study 
(PT010008).  Visit 10b will be follo wing completion of all Visi t 10a study procedures.  
â€¢Review BMD/Ocular inclusion/exclusion criteria
â€¢Confirm all visit 10a procedures  have been completed before pro ceeding to register 
subjects in IWRS 
â€¢Register subject in IWRS to conf irm participati on in the PT0100 08 and receive assigned 
treatment 
â€¢Confirm subjectâ€™s ability to use MDI correctly (provide trainin g as needed) 
â€¢Return electronic diary to subj ects and provide retraining if a ppropriate
â€¢When assigned blinded study drug  site personnel will complete p riming in the clinic 
before dispensing to the  subject for at home use 
â€¢Refer to Section 6.7 for detailed instructions for pr eparation of treatments for
administration.  These instruc tions are to be adhered to and ar e relevant to all study 
treatment visits
Confidential and Proprietary Page 67 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Record/document the dose indicat or reading. The dose indicator count recorded by the 
site staff will be dose indicat or count observed after priming but prior to subject dosing. 
Refer to  Section 7.2.1.3 for more details
â€¢Subject will administer dose of study drug at home in the eveni ng 
Note: During the study subjects will continue on the same treatment t hat they were 
assigned in Study PT010006. 
â€¢Subjects will be instr ucted to bring their eDiary and all study  medication (including used 
study drug, replacement MDI kit and sponsor-provided rescue Ven tolin HFA) to the next 
scheduled clinic visit 
â€¢Schedule ophthalmologi c assessment to occur prior to Visit 11 ( Week 28)  
â€¢Schedule visit 11 to occur after ocular assessments are conduct ed and ensure subject has
adequate supply of study drug inc luding a replacement MDI kit a nd sponsor-provided 
rescue Ventolin HFA
8.4 Visits 11 (Week 28) 
â€¢Confirm scheduled oc ular assessments have been conducted (Visit  11 should be 
rescheduled if ocular assessmen ts not conducted prior to this v isit)  Please refer to the 
exclusion criteri a exception noted in  Section 5.2.2  to see if the ocular assessment applies 
to this visit.
â€¢Review and verify subjectâ€™ s eligibility to continue
â€¢Collect study drug including sponsor-provided Ventolin HFA
â€¢Determine time of last dose of short-acting bronchodilator and other COPD medications 
(if <6 hours, the visit must be rescheduled) 
â€¢Confirm the subject took their last dose of randomized study me dication as scheduled.  
If the time of dosing was not in accordance with the protocol, then the visit must be 
rescheduled
â€¢Review subject diary for data collection compliance. Review EXAC T for completion as 
part of the eDiary review
â€¢Review smoking status and prior/concomitant medications
â€¢Review all prior medications and e nsure adherence to COPD regim en 
â€¢Record COPD exacerbations and AEs (if any) 
â€¢Obtain vital signs within 60 minutes prior to dosing 
â€¢Return electronic diary to subjects and provide retraining if a ppropriate
â€¢Prior to dosing, site personnel will use IWRS to assign subject s a new kit of study drug 
for in-clinic dosing and to continue dosing at home until the n ext scheduled visit 
â€¢For new MDIs, the recorded count w ill be the count following th e priming of the device 
but before the subjec t doses.  Refer to Section 7.2.1.3 for more details
Confidential and Proprietary Page 68 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Administer in-clinic study drug dosing from the new kit assigne d at the visit
â€¢Obtain vital signs 30 minutes post study drug dosing
â€¢Subjects will be instructed to tr ack study drug dosing in their  electronic diary between 
study clinic visits
â€¢Subject will be instructed to dose while at home from the site- primed MDI only, unless 
all of the following replacement conditions are met:
o Dose indicator is i n the red zone (See  Appendix 1 for dose indicator reading 
instructions)  
o,IWKHGRVHLQGLFDWRUUHJLVWHUVÂ” puffs remaining, and their next scheduled study 
clinic visit is not the following day
o If these replacement conditions  are met, subjects will be instr ucted to open one of 
their replacement kits, prime the  MDI and start using for at ho me dosing until the 
next scheduled study clinic visit
o Subjects will be instr ucted to bring their eDiary and all study  medication (including 
used study drug, replacement MDI kit and sponsor-provided rescu e Ventolin HFA) 
to the next sche duled clinic visit 
â€¢Schedule next visit a nd ensure subject has adequate supply of st udy drug including two
replacement MDI and sponsor-p rovided rescue Ventolin HFA 
â€¢Follow up telephone call one day  prior to scheduled visit 
8.5 Visit 12 (Week 36)
â€¢Confirm subject eligibility to continue
â€¢Collect study drug including sponsor-provided Ventolin HFA
â€¢Determine time of last dose of short-acting bronchodilator and other COPD 
medications (if <6 hours, the visit must be rescheduled)
â€¢Confirm the subject took their last dose of randomized study me dication as scheduled.
If the time of dosing was not in accordance with the protocol, then the visit must be 
rescheduled  
â€¢Review subject diary for data collection compliance. Review EXA CT for completion 
as part of the eDiary review
â€¢Review smoking status and prior/concomitant medications 
â€¢Review all concomitant medications and ensure adherence to COPD  regimen
â€¢Record COPD exacerbations and adverse events (if any)
â€¢Obtain vital signs within 60 minutes prior to dosing
â€¢Obtain 12-lead ECG within 60 minutes prior to study drug dosing
â€¢Perform urine pregnancy test
Confidential and Proprietary Page 69 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Obtain clinical laboratory samples prior to study drug dosing
â€¢Return electronic diary to subjects and provide retraining if a ppropriate
â€¢Prior to dosing, site personnel will use IWRS to assign subject s a new kit of study drug 
for in-clinic dosing and to continue dosing at home until the n ext scheduled visit 
â€¢Refer to Section 6.7 for detailed instructions for pr eparation of treatments for 
administration.  These instruc tions are to be adhered to and ar e relevant to all study 
treatment visits
â€¢If assigned to blinded study drug, record/document the dose ind icator readings of the 
used device and the replacement device  
â€¢For new MDIs, the recorded count w ill be the count following th e priming of the device 
but before the subjec t doses.  Refer to Section 7.2.1.3 for more details
â€¢Administer in-clinic study drug dosing from the new kit assigne d at the visit
â€¢Obtain vital signs 30 minutes post study drug dosing
â€¢Subjects will be instructed to tr ack study drug dosing in their  electronic diary between 
study clinic visits
â€¢Subject will be instructed to dose while at home from the site- primed MDI only, unless 
all of the following replacement conditions are met:
o Dose indicator is i n the red zone (See Appendix 1 for dose indicator reading 
instructions)  
o,IWKHGRVHLQGLFDWRUUHJLVWHUV Â”SXIIVUHPDLQLQJDQGWKHLU QH[WVFKHGXOHGVWXG\
clinic visit is not the following day
o If these replacement conditions  are met, subjects will be instr ucted to open one of 
their replacement kits, prime the  MDI and start using for at ho me dosing until the 
next scheduled study clinic visit
o Subjects will be instr ucted to bring their eDiary and all study medication 
(including used study drug, replacement MDI kit and sponsor-pro vided rescue 
Ventolin HFA) to the nex t scheduled clinic visit
â€¢ Schedule next visit a nd ensure subject has adequate supply of st udy drug including two
replacement MDI kits and sponso r-provided rescue Ventolin HFA 
â€¢Follow up telephone call one day  prior to scheduled visit 
8.6 Visit 13 (Week 44)
â€¢Confirm subject eligibility to continue
â€¢Collect study drug including sponsor-provided Ventolin HFA
â€¢Determine time of last dose of short-acting bronchodilator and other COPD 
medications (if <6 hours, the visit must be rescheduled)
Confidential and Proprietary Page 70 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Confirm the subject took their last dose of randomized study me dication as scheduled.  
If the time of dosing was not in accordance with the protocol, then the visit must be 
rescheduled 
â€¢Review subject diary for data collection compliance. Review EXA CT for completion 
as part of the eDiary review
â€¢Review smoking status and prior/concomitant medications
â€¢Review all concomitant medications and ensure adherence to COPD regimen
â€¢Record COPD exacerbations and adverse events (if any)
â€¢Obtain vital signs within 60 minutes prior to dosing
â€¢Return electronic diary to subjects and provide retraining if a ppropriate
â€¢Prior to dosing, site personnel will use IWRS to assign subjects  a new kit of study drug 
for in-clinic dosing and to continue dosing at home until the n ext scheduled visit 
â€¢Refer to Section 6.7 for detailed instructions for pr eparation of treatments for 
administration.  These instruc tions are to be adhered to and ar e relevant to all study 
treatment visits
â€¢If assigned to blinded study drug, record/document the dose ind icator readings of the 
used device and the replacement device  
â€¢For new MDIs, the recorded count w ill be the count following th e priming of the device 
but before the subjec t doses.  Refer to Section 7.2.1.3 for more details
â€¢Administer in-clinic study drug dosing from the new kit assigne d at the visit
â€¢Obtain vital signs 30 minutes post study drug dosing
â€¢Subjects will be instructed to tr ack study drug dosing in their  electronic diary between 
study clinic visits
â€¢Subject will be instructed to dose while at home from the site- primed MDI only, unless 
all of the following replacement conditions are met:
o Dose indicator is i n the red zone (See  Appendix 1 for dose indicator reading 
instructions)  
o,IWKHGRVHLQGLFDWRUUHJLVWHUV Â”SXIIVUHPDLQLQJDQGWKHLU QH[WVFKHGXOHGVWXG\
clinic visit is not the following day
o If these replacement condition s are met, subjects will be instr ucted to open one of 
their replacement kits, prime the  MDI and start using for at ho me dosing until the 
next scheduled study clinic visit
o Subjects will be instr ucted to bring their eDiary and all study  medication 
(including used study drug, replacement MDI kit and sponsor-pro vided rescue 
Ventolin HFA) to the nex t scheduled clinic visit
â€¢Schedule ophthalmologi c assessments and BMD assessments to occu r within two weeks 
prior to Visit 14 (Week 52)  
Confidential and Proprietary Page 71 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Schedule visit 14 to occur after ocular assessments and BMD ass essments are 
conducted and ensure subject has a dequate supply of study drug i ncluding two
replacement MDI kits and sponso r-provided rescue Ventolin HFA 
â€¢Follow up telephone call one day  prior to scheduled visit 
8.7 Visit 14 (Week 52; Final Visit) 
â€¢Confirm ocular assessments were conducted prior to this visit ( Visit 14 should be 
rescheduled if ocular assessmen ts not conducted prior to this v isit) Please refer to the 
exclusion criteri a exception noted in Section 5.2.2 to see if the ocular assessment 
applies to this visit
â€¢Confirm  BMD assessments were c onducted prior to this visit (Vi sit 14 should be 
rescheduled if BMD assessment  not conducted prior to this visit ) 
â€¢Confirm subject eligibility to continue
â€¢Collect study drug including sponsor-provided Ventolin HFA
â€¢Determine time of last dose of short-acting bronchodilator and other COPD 
medications (if <6 hours, the visit must be rescheduled)
â€¢Confirm the subject took their last dose of randomized study me dication as scheduled.  
If the time of dosing was not in accordance with the protocol, then the visit must be 
rescheduled 
â€¢Review subject diary for data collection compliance. Review EXA CT for completion 
as part of the eDiary review
â€¢Review smoking status and prior/concomitant medications
â€¢Perform physical examination, including weight 
â€¢Review all concomitant medications and ensure adherence to COPD  regimen
â€¢Record COPD exacerbations and adverse events (if any)
â€¢Obtain vital signs 
â€¢Perform serum pregnancy test
â€¢Obtain 12-lead ECG 
â€¢Obtain clinical laboratory samples  
â€¢Collect subject eDiary
â€¢Inform subject about reporting all SAEs up to 14 days following  the last dose of study 
drug 
â€¢Return subject to pre-study or appr opriate maintenance COPD med ications 
â€¢Schedule the follow-up telephone c all at least 14 days from Vis it 14 
Confidential and Proprietary Page 72 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
8.8 Unscheduled Visit and Treatment Discontinuation/Withdrawal Visit 
Repeat assessments, if needed, w ill be captured in unscheduled visits. 
Premature discontinuations vis its will be captured as unschedul ed visits.  The following 
minimum procedures should be compl eted at the Premature Discont inuation Visit:
xCollect all study drugs 
xRecord COPD exacerbations and adverse events (if any)
xReview concomitant medications
xConduct a physical examina tion, including vital signs 
xPerform ECG and collect blood sampl es for hematology and chemis try 
xCollect a blood sample for pregna ncy test for women of child be aring potential 
xCollect subject eDiary
xInform subject about reporting all SAEs up to 14 days following  the last dose of study 
drug 
xReturn subject to pre-study or appr opriate maintenance COPD med ications
xCapture the subject discontinuation reason 
xSchedule a follow-up telephone c all (TC) 14 days post last stud y drug dosing.  If the 
discontinuation visit is performed > 14 days post last study dr ug dosing a follow-up 
TC will not be required 
xSchedule ocular assessmen ts as early as practical
xIf after Visit 10b (Week 24), sche dule BMD measurement  as earl y as practical
8.9 Follow-up Telephone Call 
Subjects will be followed-up with in 14 days after the last stud y drug dosing.  The following 
information will be requested: 
â€¢Review previously on-going COPD e xacerbations and AEs (if any)
â€¢Review concomitant medications
Note:   For subjects who withdraw cons ent, schedule a follow-up TC at  least 14 days after 
the last study drug dosing unle ss the visit is performed >14 da ys post last study drug dosing, 
a follow-up TC will not be requi red.  For treatment discontinua tion subjects, a telephone 
follow-up call is not required as long as at least one post tre atment study visit is completed.
8.10 Vital Status Confirmation at Week 52 
All subjects who discontinue study  treatment after Visit 10b wi ll have their vital status 
confirmed at 52 weeks post-randomization. 
To confirm the vital status and cause of death, if appropriate,  the following attempts will be 
made:
Confidential and Proprietary Page 73 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢The first and second attempts m ay be conducted a s telephone fol low-up call to the subject 
within 2 weeks after 52 weeks post-randomization
â€¢The third attempt will be by certified mail to the subjectâ€™s ad dress provided at the time of 
informed consent within 3 weeks after 52 weeks post-randomizati on 
â€¢The fourth attempt will be made as a telephone follow-up call t o the next of 
kin/emergency contact provided at the time of informed consent within 4 weeks 52 weeks 
post-randomization 
â€¢A fifth attempt will be made through a certified letter to the next of kin/emergency 
contact provided at the time of i nformed consent within 5 weeks  after 52 weeks post-
randomization 
After the fifth attempt, the study site will contact the nation al death registries (if available in 
that country) to confirm date and cause of death. 
8.11 Completion of Study 
The investigator will document the completion or the reason for  early withdrawal by a 
subject in the eCRF.  The followi ng categories should be used t o describe these e vents in the 
eCRF:
â€¢Subject discretion (document reason) 
â€¢Investigator considers it to be i n the best interest of the sub ject 
â€¢Adverse events(s)
â€¢Administrative reasons (e.g., early termination of the study) 
â€¢Subject lost-to-follow-up 
â€¢Lack of efficacy
â€¢Major protocol violation 
â€¢Death
â€¢Completion of the study 
â€¢Protocol specified criteria su ch as heart rate, systolic or dia stolic blood pressure, or use of 
prohibited medications (see Section 5.7)
Confidential and Proprietary Page 74 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9 PLANNED STATISTICAL METHODS
9.1 Introduction 
This Study PT010008 will be conduc ted in a subset of US sites p articipating in Study 
PT010006, and will evaluate the f ollowing treatments: 
â€¢%*)0',ÈJ%,'
â€¢*))0',ÈJ%,'
â€¢%))0',ÈJ%,'
Across these sites, it is pla nned that approximately 500 subjec ts randomized to double-blind 
treatment only will pr ovide approximately  425 subjects who will  complete the study. 
Subjects will receive the same tr eatment (BGF MDI, GFF MDI, or BFF MDI) they were 
randomized to in Study PT010006. S ubjects randomized to open-lab el Symbicort TBH will 
not be enrolled in this study.  
This study will evaluate the saf ety of BGF MDI, BFF MDI, and GF F MDI on bone mineral 
density (BMD) measurement and ophthalmologic assessment.  
Baseline and demographic charact eristics will be collected in S tudy PT010006 with the 
exceptions of baseline BMD and lenticular opacity and ocular pr essure measurements. 
Baseline BMD and lenticular opaci ty and ocular pressure measure ments will be performed 
prior to Visit 4 (Randomization)  of Study PT010006. A separate informed consent will be 
obtained for subjects partic ipating in Study PT010008. 
9.2 Protocol Variables
All efficacy assessments are rel ative to baseline assessments o btained at Screening (Visits 1 
to 3) in Study PT010006.   
9.2.1 Study Endpoints
9.2.2 Primary Bone Mineral Density Endpoint 
â€¢Percent change from baseline in B MD of the lumbar spine measure d using DEXA scans 
of L2-L4 at Week 52
9.2.3 Other Bone Mineral Density Endpoints
xPercent change from baseline i n BMD of the hip measured using D EXA scans at Week 
52 and at EoT
xPercent change from baseline in B MD of the lumbar spine measure d using DEXA scans 
of L2-L4 at EoT 
Confidential and Proprietary Page 75 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9.2.4 Primary Ocular Endpoint
â€¢Change from baseline in the  LOCS III (P) Score at Week 52
9.2.5 Other Ocular Endpoints
â€¢Change from baseline in each scale of the LOCS III scores at We ek 28, Week 52 (NO, 
NC, and C only), and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK/2&6 ,,,JUDGHLQFUHDVHVRIÂ•& ODVVÂ•&ODVVRU
Â•&ODVVXQLWVLQHDFKRI WKHVFDOHVDW:HHN:HHN DQG(R7
â€¢Change from baseline in intraoc ular pressure (IOP) at Week 28, Week 52, and EoT 
â€¢3URSRUWLRQRIVXEMHFWVZLWK,23Â•PP+JDW:HHNDW:HHN DQG(R7
â€¢3URSRUWLRQRIVXEMHFWVFKDQJHIURP EDVHOLQHLQ,23RIÂ•PP+JDW :HHNDW:HHN
and EoT 
â€¢Change from baseline in LogMAR visual acuity using ETDRS charts  at Week 28, Week 
52, and EoT 
â€¢Change from baseline in horizont al cup-to-disc ratio at Week 28 , Week 52, and EoT 
â€¢Incidence of ocular TEAEs including cataract and glaucoma
9.2.6 Safety Endpoints
The safety endpoints for this study include: 
â€¢Adverse events (AEs)
â€¢12-lead electrocardiograms (ECGs)
â€¢Clinical laboratory testing
â€¢Vital sign measurements
9.2.7 Efficacy Endpoints
â€¢Change from baseline in average  daily rescue Ventolin HFA (albu terol sulfate) use.
â€¢Percentage of days with no res cue Ventolin HFA use 
â€¢Rate of moderate or severe COPD exacerbations
â€¢Rate of COPD exacerbations of any severity
â€¢Change from baseline in: the E XACT total score , the 11-item EXA CT Respiratory 
Symptoms (E-RS) Total Score (RS-Total Score),  as well as 3 sub scale scores symptom 
(RS-Breathlessness, RS-Cough a nd Sputum, and RS-Chest Symptoms)  over 52 weeks 
and over each 4-week interval of  the 52-week Treatment Period
Confidential and Proprietary Page 76 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9.3  Study Populations 
The following analysis populati ons are defined in this study: 
â€¢The Safety Population  will consist of all subjects enrolled in PT010008 who receive any 
amount of study medication.  Subj ects will be analyzed accordin g to treatment received 
rather than randomized.  If a s ubject received more than 1 rand omized treatment, they 
will be analyzed and i ncluded in summaries according to the tre atment they received the 
most. Subjects receiving no study  treatment will be excluded, a s will subjects who have 
no post-dose safety assessments .  (Note that a subject who used  a study treatment, but 
took less than 1 full dose of tr eatment will qualify for this p opulation).  
Note: The statement that a subject h ad no AEs also constitutes a safe ty assessment
â€¢The BMD Analysis Population is defined as all evaluabl e subjects in the Safety 
Population who have a baseline BM D assessment and at least 1 on -treatment BMD 
assessment. Subjects will be analy zed according to actual treat ment received
â€¢The Ophthalmologic Analysis Population is defined as all evaluable subjects in the 
Safety Population who have a base line ophthalmologic assessment  and at least 1 on-
treatment ophthalmologic assessmen t. Subjects will be analyzed according to actual 
treatment received 
â€¢The mITT Population is defined as the subgroup of mITT subjects from Study 
PT010006, who enrolled in PT010008. S ubjects will be analyzed a ccording to the active 
treatment they were assigned to a t randomization in Study PT010 006. (Note that a subject 
who used a study treatment, but  took less than one full dose of  treatment will qualify for 
this population).  Data from both S tudy PT010006 and Study PT01 0008 will be included 
Exclusions from the ophthalmolo gic and BMD population will be d efined in the SAP. 
Analyses will be performed as follows:
Demographics will be summarized f or the Safety Population. Demo graphics will also be 
summarized for the BMD and Ophtha lmologic Analysis populations if these are different 
from the Safety Population. Ana lyses of ophthalmologic endpoint s will be performed on the 
Ophthalmologic Analysis Popul ation, and those of BMD endpoints will be performed on the 
BMD Analysis Population. All oth er safety analyses will be pres ented for the Safety 
Population. Efficacy will be pres ented for mITT population. 
9.4 Safety Analyses
Safety data will be summarize d both cumulatively over 52 weeks using data observed during 
PT010006 and this supplemental study . Analyses involving change  from baseline will use 
baseline values from Study PT010006. 
Confidential and Proprietary Page 77 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9.4.1 Analysis of BMD Endpoints
9.4.1.1 Percent change from baseline in BMD of the lumbar spine measured using 
DEXA scans of L2-L4
The change from baseline in BMD  of the lumbar spine at Week 52 (and similarly at EoT) 
will be analyzed using an Analy sis of Covariance (ANCOVA) model  with treatment group 
and gender as categorical covari ates, and baseline BMD score, ag e, and age by gender 
interaction as con tinuous covariates. 
T- and Z- scores will be present ed as shifts from baseline to e ach time point; de tails will be 
provided in the SAP. 
9.4.1.2 Percent change from baseline in total hip BMD of the hip  measured using DEXA 
scans  
The change from baseline in B MD of the hip at Week 52 (and simi larly at EoT) will be 
analyzed similarly to the change from baseline in BMD of the lu mbar spine. 
9.4.2 Analysis of Ocular Endpoints  
9.4.2.1 Change from baseline in each of the LOCS III (NO, NC, C,  and P) scores 
Change from baseline in the LOC S III (P) scores at each post-ra ndomization visit will be 
analyzed using an Analysis of C ovariance (ANCOVA). The model wi ll include treatment 
group as a fixed effect, and baselin e LOCS III (P) score, smoki ng pack years, and age as 
continuous covariates. The model will account for inter-eye cor relation by including subject 
and eye (within subject) as random effects. 
Two-sided 95% confidence interval s will be comput ed for pairwis e differences of BGF 
minus GFF and BFF minus GFF, and non-inferiority will be declar ed if the upper confidence 
bound is less than 0.5. The analysis  of the change from baselin e in LOCS III (P) scores at 
Week 52 will be the prima ry ocular analysis, with analyses at W eek 28 and EoT being 
supportive. 
The above analyses will be repea ted for the other 3 LOCS III (N O, NC, and C) scores, but 
with the corresponding baseline LOCS III scale score as a covar iate.
9.4.2.2 Proportion of subjects with LOCS I ,,JUDGHLQFUHDVHVRIÂ•&ODVVÂ•
&ODVVRUÂ•&ODVVXQLWVLQHDFKRIWKHVFDOHV
7KHSURSRUWLRQRIVXEMHFWVZLWK/2& 6,,,JUDGHLQFUHDVHVLQHLW KHUH\HRIÂ•&ODVV
Â•&ODVVDQGÂ•&ODVV XQLWVLQHDFKRIWKHVFDOH s at Week 28, at Week 52, and at 
EoT will be summarized by treatment group. 
Confidential and Proprietary Page 78 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9.4.2.3 Change from baseline in intraocular pressure (IOP) 
The change from baseline in IOP at Week 28, Week 52, and EoT wi ll be analyzed using a 
similar model as for the LOCS III  (P) score at 52 weeks, but wi th the baseline IOP as a 
covariate.
9.4.2.4 3URSRUWLRQRIVXEMHFWVZLWK,23Â•PP+JDQGWKHSURSRUWLRQRIV XEMHFWVZLWK
FKDQJHIURPEDVHOLQHLQ,23RIÂ•PP+J
7KHSURSRUWLRQRIVXEMHFWVZLWK,23 Â•PP+JLQHLWKHUH\HDW: HHN:HHNDQG(R7
will be summarized by treatme nt group.  Similarly, the proporti on of subjects with IOP 
LQFUHDVHVIURPEDVHOLQHRIÂ•PP+JLQHLWKHUH\HDW:HHN:H HNDQG(R7ZLO l be 
summarized.  
9.4.2.5 Change from baseline in LogMAR visual acuity using ETDRS  charts 
Change from baseline in LogMAR visual activity scores will be s ummarized for each eye at 
each visit by treatment group us ing descriptive statistics.
9.4.2.6 Change from baseline in horizontal cup-to-disc ratio 
Change from baseline in horizont al cup-to-disc ratio will be su mmarized for each eye at each 
visit by treatment group us ing descriptive statistics.
9.4.2.7 Incidence of ocular TEAEs including cataract, glaucoma
The proportion of subjects with ocul ar TEAEs in each treatment group will be summarized 
overall, as well as by individua l AE. AEs qualifying as ocular AEs include cataract and 
glaucoma.
9.4.3 Adverse Events
The version of the Medical Dicti onary for Regulatory Activities  (MedDRA) that is current at 
the time of database lock will be used to code verbatim terms f or AEs for final analysis of the 
data.  The number and incidence of adverse events, serious adve rse events, adverse events of 
special interest by category,  confirmed AEs of pneumonia, and s tudy drug discontinuations 
due to adverse events will be s ummarized by treatment group.  T hey will be tabulated at the 
level of the Medical Dictionary for Regulatory Activities (MedD RA) preferred term and the 
MedDRA system organ class.  T abulations will  be broken down by severity, by relationship 
to study drug, and AEs leading t o treatment discontinuation. No  hypothesis tests will be 
performed.
9.4.4 Cardio- and Cerebrovascular Events Determined by Adjudicat ion 
Committee
CCV and Mortality Adjudication Co mmittees will review and adjud icate serious CCV events 
as MACE. MACE events are defined as the following: 
Confidential and Proprietary Page 79 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
xCardiovascular death
xNon-fatal myocardial infarction (MI)
xNon-fatal stroke 
The adjudication committees will re view and assess these non-fa tal serious CCV events 
and all deaths as to whether or not  they fulfill criteria (based  on adjudication committee 
working practices) for MACE.  
MACE events will be su mmarized by treatment group.
9.4.5 Pneumonia Events Determined by Adjudication Committee
All AEs/SAEs with preferred ter ms that could relate to pneumoni a will be adjudicated to 
provide a more complete assessm ent of all physician-reported pn eumonias. The assessment 
of pneumonia events will include  the overall rates of pneumonia . 
9.4.6 Clinical Laborat ory Measurements
Summary statistics (n, mean, med ian, standard deviation, minimu m, and maximum) for the 
baseline assessment (Day 1) and f or the pre-dose value and chan ge from baseline at pre-dose 
value of post-baseline  visits with scheduled lab assessments of  continuous laboratory 
variables, including serum potas sium and glucose will be tabula ted. 
Shift tables relative to the nor mal reference ranges will be pr oduced using the categories 
defined by the CTCAE Version 4.03 gr ades.  For these shift tabl es, for each treatment, 
the subjectâ€™s pre-dose grade will  be cross-tabulated by the sub jectâ€™s maximum post-baseline 
grade during the treatment; also, the subjectâ€™s maximum post-ba seline grade during treatment 
will be tabulated for all ba seline grades combined.
The number and percent of subject s with potentially clinically significant (PCS) lab values 
will be summarized.  Potentially c linically significant values for serum potassium are <3.0 
mmol/L or >6.0 mmol/L, and for bl ood glucose <2.2 mmol/L or >13. 9 mmol/L.  Potentially
clinically significant values fo r labs will be defined in the SA P.  No hypothesis tests will be 
performed.
9.4.7 Vital Signs
Summary statistics (mean, media n, standard deviation and range)  for absolute values 
and change from baseline values w ill be tabulated for each treat ment and assessment time. 
For vital signs, baseline valu es will be defined as the average  of the values prior to dosing 
at the randomization visit (Visit  4).  Potentially clinically si gnificant values for vital signs 
will be defined in the SAP and the  percentage of subjects with P CS values will be 
summarized.  No hypothesis tests will be performed. 
Confidential and Proprietary Page 80 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
9.4.8 Electrocardiograms
Summary statistics (mean, media n, standard deviation and range)  for raw values and 
change from baseline values in h eart rate, PR interval, QRS axis,  QRS interval, QT interval 
and QTcF interval will be calcula ted, where baseline is defined  as the average of the pre-dose 
measurements taken prior to the  start of treatment at the rando mization visit (Visit 4).  
The QTcF (Fridericia Correcte d QT) is defined as (QT/[RR1/3]).Heart rate (bpm) is 
estimated as 60,000/RR.  The se assessments will be tabulated fo r each treatment and 
assessment time.  Potentia lly clinically significant values for ECG parameters will be defined 
in the SAP, and the pe rcentage and number of subjects with PCS ECG values will be 
tabulated.  No hypothesis tests will be performed.
9.4.9 Exposure
The duration of exposure to study  medication (in days), the per son-years of exposure, the 
mean number of doses, and number a nd percentage of subjects who  are compliant will be 
summarized by treatment group.  A ll exposure summaries will be generated for the safety 
population by actual treatment received.
9.5 Analyses of Efficacy Endpoints
Analyses of efficacy will be performed using the mITT Populatio n. 
9.5.1 Rescue Ventolin HFA Use
The number of puffs of rescue Vent olin HFA taken in the previou s 12 hours will be recorded 
in the subject diary in the morni ng and evening.  For every per iod of time for w hich the mean 
number of puffs of rescue will be  calculated, missing values wi ll be ignored in both the 
numerator and denominator.  As su ch, the denominat or will be ad justed based on the number 
of days (including half days) with non-missing values.
The mean change from baseline i n rescue use will be summarized by treatment group over 52 
weeks and over each post-randomiza tion 4-week interval (Interva l 1 to Interval 13).  
9.5.2 Percentage of Days with No Rescue Ventolin HFA Use over th e Treatment 
Period
As a supportive analysis, percentage of days with â€˜no rescue Ve ntolin HFA useâ€™ over 52 
weeks will be summarized usin g descriptive statistics .  A â€˜day with no rescue useâ€™ is defined 
using rescue Ventolin HFA usage da ta from days where rescue Ven tolin HFA usage data is 
non-missing as any day where the subject reported no puffs of r escue Ventolin HFA.   
9.5.3 Chronic Obstructive Pulmonary Disease Exacerbations
The rate of moderate or severe COPD exacerbations will be summa rized by treatment group.  
Chronic obstructive  pulmonary disease exacerbations will be con sidered separate events 
provided that 7 or more days are  between the recorded stop date  of the earlier event and start 
Confidential and Proprietary Page 81 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
date of the latter.  For modera te or severe COPD exacerbations,  the start date is be defined as 
the start date of prescribed tr eatment with a systemic corticos teroid or systemic  antibiotic and 
the stop date will be defi ned as the last day  of prescribed tre atment with a systemic 
corticosteroid or systemic antib iotic. The rate of COPD exacerb ations of any severity will be 
presented in a similar manner.
Duration of COPD Exacerbation 
For moderate or severe exacerba tions, the duration is defined b y the length of prescribed 
treatment, whereas for mild ex acerbations, the duration is defi ned by the length of symptoms. 
For moderate or severe COPD ex acerbations, the start date will b e defined as the start date of 
prescribed treatment with a systemic corticosteroid or systemic  antibiotic and the stop date 
will be defined as the last day of  prescribed treatment with a systemic corticosteroid or 
systemic antibiotic. In order to e nsure that the same event is not counted twice, concurrent 
moderate or severe COPD exacer bations with sta rt and stop dates  equal to or less than 7 days 
apart will be considered the sam e event and assigned the maximu m severity between the two.  
For mild COPD exacerbations, sta rt date will be de fined as the onset of worsened symptoms 
as recorded by the subject in t he eDiary, and the stop date wil l be defined as the last day of 
worsened symptoms.  In order to e nsure that the same event is n ot counted twice, mild COPD 
exacerbations with start and stop da tes equal to or less than 7  days apart will be considered 
the same event.  
In addition, in order to not double count exacerbations that ar e moderate or severe, eDiary 
data from dates within 7 days of a moderate or severe exacerbat ion will not be included as 
additional mild COPD exacerbati ons.  This implies that continui ng worsened symptoms that 
meet the definition of a mild e xacerbation would need to be pre sent at least 2 days prior to 
the 7-day period immediately preceding the start date of a mode rate or severe COPD 
exacerbation in order to be consid ered a separate event.  Simil arly, worsened symptoms 
would need to be present for at l east 2 days after the 7-day pe riod immediately following a 
moderate or severe COPD exacerba tion to be considered a separat e event.  
9.5.4 Exacerbations of Chronic Pulmonary Disease Tool (EXACT)
The EXACT is a 14-item PRO daily  diary which will be used to me asure the effect of 
treatment on exacerbations, and on the  severity of respiratory symptoms.  The E-RS is an 
11-item subset which will be use d to measure the effect of trea tment on the severity of 
respiratory symptoms.  Mean chang e from baseline in: the daily EXACT Total Score, the 
daily total symptom score (RS-Total Score), as well as 3 subscal e scores, RS-Breathlessness, 
RS-Cough and Sputum, and RS-Chest Symptoms, will be calculated over each 4-week 
interval of the 52-week Treatme nt Period.  The last 7 days of t he Screening Period from lead-
in Study PT010006 will be used to cal culate the baseline.  The mean change from baseline 
in RS-Total Score, RS- Breathlessness, RS- Cough and Sputum, and R S-Chest Symptoms will 
be summarized by treatment g roup over 52 weeks and over each po st-randomization 4-week 
interval (Interval 1 to Interval 13). 
Confidential and Proprietary Page 82 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
10 ADMINISTRATIVE CONSIDERATIONS
10.1 Regulatory Authority Approval
Pearl will obtain approval to conduc t the study from the approp riate regulatory agency in 
accordance with any applicable count ry-specific regulatory requ irements prior to a site 
initiating the study in that country.
10.2 Ethical Conduct of the Study and Institutional Review Boar d or 
Independent Ethics Committee Approval 
The study will be conducted in accordance with Good Clinical Pr actice (GCP).  These 
standards respect the following guidelines: 
â€¢ Guideline for Good Clinical Pr actice E6 (R1):  Consolidated G uideline (International 
Conference on Harmonization of Tec hnical Requirements for the R egistration of 
Pharmaceuticals for Human Use, May 1996). 
â€¢ US CFR dealing with clinical studies (21 CFR parts 50, 54, 56,  and 312). 
â€¢ Declaration of Helsinki, concer ning medical research in humans  (Ethical Principles for 
Medical Research Involving Hum an Subjects) [http://www.wma.net/ en/10home/index.html]. 
â€¢ Any additional regulatory requirements.The Investigator (or Pearl, whe re applicable) is responsible fo r ensuring that this protocol, 
the siteâ€™s ICF, and any other in formation that will be presente d to potential subjects (eg, 
advertisements or information t hat supports or supplements the ICF) are reviewed and 
approved by the appropriate IRB/I EC.  The Investigator agrees t o allow the IRB/IEC direct 
access to all relevant document s.  The IRB/IEC must be constitu ted in accordance with all 
applicable regulatory requirements.
Pearl will provide the Investigato r with relevant document(s)/d ata that are needed for 
IRB/IEC review and approval of t he study.  If the protocol, the  ICF, or any other information 
that the IRB/IEC has approved for  presentation to potential sub jects is amended during the 
study, the Investigator is responsible for ensuring the IRB/IEC  reviews and approves, where 
applicable, these amended documen ts.  The Investigator must fol low all applicable regulatory 
requirements pertaining to the us e of an amended ICF including obtaining IRB/IEC approval 
of the amended form before new s ubjects consent to take part in  the study using this version 
of the form.  The IRB/IEC approva l of the amended ICF/other inf ormation and the approved 
amended ICF/other information m ust be forwarded to Pearl prompt ly. 
10.3 Subject Information and Consent 
The study will be conducted in acco rdance with applicable subje ct privacy requirements.  
The proposed ICF, which must be i n compliance with applicable r egulations, must be 
reviewed and approved by the IRB/ IEC and Pearl prior to initiat ion of the study.   
Confidential and Proprietary Page 84 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
The Investigator will be respons ible for obtaining written info rmed consent from potential 
subjects prior to any study-speci fic screening and entry into t he study.  A copy of the signed 
ICF will be provided to the subj ect.  The original will be reta ined by the Investigator. 
10.4 Laboratory Accreditation
Any laboratory facility intende d to be used for a nalysis of cli nical laboratory samples 
required by this protocol must pr ovide evidence of adequate lic ensure or accreditation 
according to the prevailing regulations in that state and/or co untry.  Reference values and/or 
normal ranges for the test re sults must be provided to Pearl.  Pearl must be notified promptly 
in writing of any changes occurring in reference values during the course of the study.
10.5 Confidentiality 
10.5.1 Confidentiality of Data
By signing this protocol, the In vestigator affirms to Pearl tha t information furnished to the 
Investigator by Pearl will be m aintained in confidence and such  information will be divulged 
to the IRB/IEC, or similar or e xpert committee; affiliated inst itution; and employees only 
under an appropriate und erstanding of confide ntiality with such  board or committee, 
affiliated institution a nd employees.  Data generated by this s tudy will be considered 
confidential by the Investigator , except to the extent that it is included in a publication.
10.5.2 Confidentiality of Subject/Patient Records
By signing this protocol, the In vestigator agrees that Pearl (o r representative), IRB/IEC, or 
Regulatory Agency representatives  may consult and/or copy study  documents in order to 
verify worksheet/case report fo rm data.  By signing the consent  form, the subject/patient 
agrees to this process.  If s tudy documents will be photocopied  during the process of 
verifying worksheet/case report form information, the subject/p atient will be i dentified by 
unique code only; full names/initia ls will be masked prior to t ransmission to Pearl.  In 
addition, the Investigator agrees  to treat all subject data use d and disclosed in connection 
with this study in accordance w ith all applicable laws (i.e., H ealth Insurance Portability and 
Accountability Act), rul es and regulations. 
10.6 Quality Control and Assurance
Pearl is responsible for impleme nting and maintaining quality c ontrol and quality assurance 
systems with written SOPs to ens ure that Studies are conducted and data are generated, 
documented, and reported i n compliance with the protocol, accep ted standards of GCP, and 
all applicable federal, state, a nd local laws, rules and regula tions relating to  the conduct of 
the clinical study.
10.7 Data Management 
Data management procedures and i nformation for this protocol wi ll be provided by Pearl or 
their designee.
Confidential and Proprietary Page 85 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
10.8 Study Monitoring 
In accordance with applicable regulations, GCP, and Pearl proce dures, clinical monitors will 
contact the site prior to subject enrollment to review the prot ocol and data collection 
procedures with site staff.  In  addition, the monitor will peri odically contact the site, 
including conducting on-site vi sits.  The extent, nature, and f requency of on-site visits will be 
based on such considerations as th e study objective and/or endp oints, the purpose of the 
study, study design complexity, and enrollment rate. 
During these contacts, the monitor will:
â€¢Check the progress of the study 
â€¢Review study data collected
â€¢Conduct source document verification 
â€¢Identify any issues and address their resolution 
This will be done in order to verify that the: 
â€¢Data are authentic, ac curate, and complete
â€¢Safety and rights of subjects are being protected
â€¢Study is conducted in accordance with the currently approved pr otocol (and any 
amendments), GCP, and all appli cable regulatory requirements 
The Investigator agrees to allow the monitor direct access to a ll relevant documents and to 
allocate his/her time and the time of his/her staff to the moni tor to discuss findings and any 
relevant issues.
Upon completion of the study, the  monitor will conduct the foll owing activities in 
conjunction with the Investigator  or site staff, as appropriate :
â€¢Return of all study data to Pearl 
â€¢Data queries 
â€¢Accountability, reconciliation, and a rrangements for unused inv estigational 
product(s) 
â€¢Review of site study records for completeness
After the final review of the s tudy files, the files should be secured for the appropriate time 
period as specified in Section 10.9. The Investigator will also pe rmit inspection of the study 
files by Pearlâ€™s Quality Assura nce auditors, and authorized rep resentatives of the FDA or 
other applicable regulatory agencies.
Confidential and Proprietary Page 86 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
10.9 Retention of Data 
Documents that individually and collectively permit evaluation of the conduct of the study 
and the quality of the data produce d must be maintained for rev iew by Pearlâ€™s quality 
assurance auditors and by all a pplicable regulatory authorities .  The period of time these 
documents must be maintained is g overned by applicable regulati ons.  Pearl or its designee 
will inform the Investigator when these documents may be destro yed.  Pearl or its designee 
must be notified in writing at least  6 months prior to the intende d date of disposal of any 
study record related to this pr otocol to allow Pearl to make al ternate storage arrangements.
10.10 Financial Disclosure 
The Principal Investigator or s ub-Investigators named on the Fo rm FDA 1572 or the locally 
accepted alternate Investigator S tatement form, will need to co mplete a financial disclosure 
form prior to study initiation, at any time during the study ex ecution if new information 
needs to be disclosed, and for 1 year after study completion.  Investigators should make the 
IRB/IEC aware of any financial i nterests that the Investigator has in the investigational 
product. 
10.11 Investigator's Final Report 
Shortly after completion of the  Investigator's participation in  the study, the Investigator will 
submit a written report to Pearl.
10.12 Publication Policy 
Pearl intends to publish the resu lts of all of the clinical stu dies that it sponsors in compliance 
with the Declaration of Helsi nki (http://www.wma.net/en/10home/ index.html).  Consistent 
with the recommendations  of the editors of several leading medi cal journals, the International 
Committee of Medical Journal Editors (ICMJE), authorship of pub lications resulting from 
Pearl -sponsored studies should f airly recognize the activities  of those that have made a 
significant contribution to the study.  Thus, it is anticipated  that authorship will reflect the 
contribution made by Pearl pers onnel, the Investigators and oth ers involved, such as 
statisticians.
In recent years, issues about conflicts of interest and accurac y of the study data have been 
raised in the medical press.  Acco rdingly, Pearl has developed publication guidelines as 
described below:
1.Responsibility: Each Principal Investigator is re sponsible for the accuracy and  
completeness of all da ta from their site.  Pearl (or its repres entatives) is responsible for 
the accuracy of the data entere d into the study databases and f or the accuracy of the 
analyses conducted.
2.Sponsor Review of Ext ernal Manuscripts: Consistent with the previous bullet point, 
drafts of any and all publications  or presentations that may ar ise from this study must be 
submitted at least 30 days prior to submission for publication or presentation to Pearl for 
Confidential and Proprietary Page 87 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
review, approval, and to ensure c onsistency with the policy in this protocol.  Pearl will 
have the right to request appr opriate modification to correct f acts and to represent its 
opinions, or the opinions of the  publication committee, if thes e differ with the proposed 
publication. 
3.Confidentiality: Investigators will conduct all in teractions with Pearl and with  third 
parties consistent with the executed confidentiality agreements .  While publication, by 
intention, presents the critical  scientific data  in a public fo rum, some information (such as 
future plans, results of nonclini cal studies, or chemical formu lae) may still need to remain 
confidential. 
4.Medical Journal Review: Consistent with the intenti on of Pearl to publish the study in a 
fair and accurate manner, Pear l supports diligence in the publi cation review process of 
medical journals.  Accordingly , upon request, all pertinent stu dy data and information 
will be made available as supplem ental information for journal editors and reviewers to 
evaluate and audit, e.g., protoco l and amendments, data tabulat ions.  The journal and 
reviewers will need to make arra ngements to maintain the confid entiality of such 
supplemental information, where  relevant, and Pearl will make s uitable arrangements to 
ensure that the identity of jour nal reviewers is kept confident ial.  Records will be 
maintained of reviewers and the  respective doc uments and datase ts that were reviewed by 
each of them.
5.Reporting of Clinical Trial Results:   To provide transparenc y in the conduct and 
reporting of randomized clinical t rials, Pearl reports clinical  findings based on the 
guidance of The CONSORT (Consolid ated Standards of Reporting Tr ials) Statement 
(CONSORT, 2010 ) and a 25-item checklist which is  intended to improve the repo rting of 
a randomized controlled Study,  and to facilitate r eader underst anding of the Study design, 
conduct, analysis and interpr etation, and to support their abil ity to assess the validity of 
its results.
6.Internet Clinical  Trial Listing: In addition, also consistent  with the recommendations of 
the ICMJE, Pearl will make availa ble appropriate  information re garding the study via the 
internet.  This will include reg istration and listing of the st udy on www.clinicaltrials.gov,
the US National Institutes of Health listing of clinical trials , and other clinical trial 
listings as appropriate (e.g., E UdraCT; https://eudract.ema.eur opa.eu).  Per AstraZeneca 
policy, Pearl posts clinical study  protocols for public viewing  when a manuscript is 
published in a medical journal .  Prior to being made public, th e protocol is reviewed by 
AstraZeneca Intellectual Property.
Confidential and Proprietary Page 88 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
12 APPENDICES
Appendix 1 Dose Indicator Reading 
For the purposes of this study, when recording the dose indicat or display value, review the 
indicator display at the top of t he MDI and record the number o f inhalations remaining that 
matches the chart below: 
130 Count (Actuation) Version Shown  
 
If your dose 
indicator 
display looks 
like this record 
120+   
If your dose 
indicator 
display looks 
like this record 
120  
If your dose 
indicator 
display looks 
like this record 
110  
If your dose 
indicator 
display looks 
like this record 
100  
If your dose 
indicator
display looks 
like this record 
90 
 
If your dose 
indicator 
display looks 
like this record 
80  
If your dose 
indicator 
display looks 
like this record 
70  
If your dose 
indicator 
display looks 
like this record 
60  
If your dose 
indicator 
display looks 
like this record 
50  
If your dose 
indicator
display looks 
like this record 
40 
 
If your dose 
indicator 
display looks 
like this record 
30  
If your dose 
indicator 
display looks 
like this record 
20  
If your dose 
indicator 
display looks 
like this record 
10  
If your dose 
indicator 
display looks 
like this record 
0  
Confidential and Proprietary Page 90 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢The Dose indicator  number will continue to cha nge after every 20 puffs. 
â€¢When the number in the Dose indicator  window changes to 20 and t he color behind the 
number changes to red, this mean s that there are only 20 puffs left in your inhaler. See 
Figure 2d.
Figure 2d
Preparing the Inhaler for Use : 
The inhaler comes in a foil pouc h that contains a drying packet  (desiccant).
â€¢Take the inhaler out  of the foil pouch. 
â€¢Throw away the pouch and the dr ying packet.  Do not eat or inha le the contents of the 
drying packet.  
â€¢Remove the Cap from the Mouthpiece as shown in Figure 3.   
Figure 3
Figure 2b
110 puffs
Figure 2a
120 puffs
Figure 2c
100 puffs
Confidential and Proprietary Page 92 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Prime the inhaler be fore you use it for the first time.
Priming the Inhaler:
â€¢Check inside the Mouthpiece  for objects before use. 
â€¢Hold the Actuator with the Mouthpiece  pointing away from you and others as shown in 
Figure 4a . 
â€¢Shake the inhaler well before each puff. 
â€¢Push down fully on the center ( not â€˜off centerâ€™) of the Dose indicator  on top of the 
Canister  (see Figure 1 ) until the Canister  stops moving in the Actuator to release a 
puff from the Mouthpiece as shown in Figure 4b .  Note:  It is normal to hear a soft click 
from the dose indicator as it counts down during use. 
â€¢Repeat this priming step 3 mor e times for a total of 4 times, s haking the inhaler each time 
before you press it. 
â€¢After completing the 4 priming  puffs, your inhaler is now prime d ready to use for the first 
time.
You must re-prime your inhaler again if you have not used it in  more than 7 days.  Take the 
cap off the mouthpiece and shake  and spray the inhaler 2 times into the air away from your 
face.
Using the Inhaler:
Your dose of medicine comes from 2 puffs  from the inhaler. 
Refer to Figure 5 for Step 1 through Step 8. 
â€¢Step 1 : Remove the Cap from the Mouthpiece . 
â€¢Step 2 : Shake the inhaler well before each puff.
â€¢Step 3 : While holding the inhaler with the Mouthpiece  pointing towards you breathe out 
through your mouth to empty as much air from your lungs as poss ible. 
Figure 4a Figure 4b
Confidential and Proprietary Page 93 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Step 4 :  Close your lips around the Mouthpiece and tilt your head back slightly to make 
sure your tongue is away from the Mouthpiece . 
â€¢Step 5 : Take a deep breath in ( inhale) slowly through your mouth whil e pressing down 
firmly on the center (not  â€˜off centerâ€™) of the Dose indicator until the Canister  stops 
moving in the Actuator and a puff has been release d. Then, stop pressing the Dose 
indicator .
â€¢Step 6 : When you have finished br eathing in, remove the Mouthpiece  from your mouth 
and hold your breath for 10 seconds  or as long as comfortable.    
â€¢Step 7 :  Then, breathe out normally. 
Take your second puff of medicine by repeating Step 2 through S tep 7.  
â€¢Step 8: Replace the Cap back on the Mouthpiece.
Confidential and Proprietary Page 94 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure 5 
How to clean  the Inhaler : 
It is very important to keep you r inhaler clean so medicine wil l not build-up and block the 
spray through the Mouthpiece.  See Figure 6 .
Confidential and Proprietary Page 95 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure 6
The Canister  should be gently pulled from the top of the Actuator once a week and the 
Actuato r cleaned.  Do not clean the  Canister or let it get wet.
Confidential and Proprietary Page 96 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Step 1 : Pull the Canister  out of the Actuator as shown in Figure 7.
Figure 7
â€¢Step 2 :  Set the Canister aside where it will not get wet.
â€¢Step 3 : Take the Cap off the Mouthpiece.
â€¢Step 4:   Rinse the Actuator  through the top with warm r unning water for 30 seconds.  
Then rinse the actuator ag ain through the Mouthpiece ( see Figure 8 ). 
Figure 8
â€¢Step 5:   Shake all of the wat er droplets out of the Actuator . 
â€¢Step 6: Look in the Actuator  and the Mouthpiece to make sure it is clean and clear .
Confidential and Proprietary Page 97 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Repeat Step 4  through Step 6 , until the Actuator and the Mouthpiece are clean and clear.
â€¢Step 7: Let the Actuator  dry completely, such as overnight as shown in Figure 9 .Do 
Not put the Canister  back into the Actuator if it is still wet.
Figure 9
Reassembly of the Inhaler and In structions for Use after Cleani ng:
â€¢After the Actuator is completely dry, gently press the Canister  down in the Actuator as 
shown in Figure 10 .It is not necessary to press down on the Canister  hard enough to 
cause a puff to be released.
Figure 10
Confidential and Proprietary Page 98 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
â€¢Re-prime your inhaler 2 times after each cleaning.
â€¢Hold the Actuator with the Mouthpiece  pointing away from you and others as shown in 
Figure 4 . 
â€¢Shake the inhaler well before each puff. 
â€¢Push down fully on the center ( not â€˜off centerâ€™) of the Dose indicator  on top of the 
Canister until the Canister  stops moving in the Actuator to release a puff from the
Mouthpiece . 
â€¢Repeat this re-priming step 1 m ore time for a total of 2 times.
â€¢After re-priming your inhaler  2 times, your inhaler is now read y to use. 
Confidential and Proprietary Page 99 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Appendix 3 Instructions for Use of Ventolin HFA Inhalation Aero sol 
Device 
Instructions for Use
For Oral Inhalation Only Your VENTOLIN HFA inhaler
â€¢The metal canister holds the medicine. See Figure A.
Figure A 
Figure A 
The canister has a counter to show how many sprays of medicine you have left. The 
number shows through a window in the back of the actuator. See Figure B.
Confidential and Proprietary Page 100 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure B
â€¢The counter starts at either 204 or 064, depending on which size inhaler you have. The 
number will count down by 1 each time you spray the inhaler. Th e counter will stop 
counting at 000. 
â€¢Do not try to change the numbers or  take the counter off the me tal canis ter. The counter 
cannot be reset, and it is permane ntly attached to the canister .
â€¢The blue plastic actuator sprays  the medicine from the canister . The actuator has a 
protective cap that covers the mouthpiece. See Figure A . Keep the protective cap on the 
mouthpiece when the canister is n ot in use. The strap keeps the  cap attached to the 
actuator.
â€¢Do not use the actuator with a canister  of medicine from any other inh aler.
â€¢Do not use a VENTOLIN HFA canister wit h an actuator from any other inh aler.
Before using your VENTOLIN HFA inhaler
Before you use VENTOLIN HFA for the first time, you must prime the inhaler so 
that you will get the right amount of medicine when you use it.
To prime the inhaler, take the cap off the mouthpiece and shake  the inhaler well. Then 
spray the inhaler 1 time into the air away from your face. See Figure C . Avoid spraying 
in eyes.
Confidential and Proprietary Page 101 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure C
Figure C
â€¢Shake and spray the inhaler lik e this 3 more times to finish pr iming it. The counter should 
now read 200or 060, depending on which size inhaler you have. See Figure D.
Figure D
Figure D
You must prime your inhaler again if you have not used it in mo re than 14 days or if you 
drop it. Take the cap off the mouthpiece and shake and spray th e inhaler 4 times into the 
air away from your face.
Confidential and Proprietary Page 102 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
How to use your VENTOLIN HFA inhaler 
Follow these steps every time you use VENTOLIN HFA.
Step 1. Make sure the canister fits fir mly in the actuator. The counter  should show through 
the window in the actuator. Shake the inhaler well before each spray.
Take the cap off the mouthpiece  of the actuator. Look inside th e mouthpiece for foreign 
objects, and take out any you see. Step 2. Hold the inhaler w ith the mouthpiece down. See Figure E.
Figure E 
Step 3. Breathe out through your mouth a nd push as much air from your l ungs as you can. 
Put the mouthpiece in your mouth and close your lips around it.  See Figure F.
Figure F 
Step 4. Push the top of the canister all the way down while you breathe in deeply and slowly 
through your mouth. See Figure F.
Confidential and Proprietary Page 103 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Step 5. After the spray comes out, take your finger off the canister. A fter you have breathed 
in all the way, take the inha ler out of your mouth and close yo ur mouth. 
Step 6 .Hold your breath for  about 10 s econds, or for as long as is comfortable. Breathe 
out slowly as long as you can. 
If your healthcare provider ha s told you to use more sprays , wait 1 minute and shake the 
inhaler again. Repeat S teps 2 through Step 6. 
Step 7. Put the cap back on the mouthpiece after every time you use the  inhaler. Make sure it 
snaps firmly into place. 
Cleaning your VENTOLIN HFA inhaler
Clean your inhaler at least 1 time each week. You may not see a ny medicine build-up on the 
inhaler, but it is important t o keep it clean so medicine build -up will not block the spray. See 
Figure G.
Figure G
Step 8. Take the canister out of the act uator, and take the cap off the  mouthpiece. The strap 
on the cap will stay atta ched to the actuator.
Step 9. Hold the actuator under the fau cet and run warm water through i t for about 30 
seconds. See Figure H.
Confidential and Proprietary Page 104 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure H
Step 10. Turn the actuator upside down and r un warm water through the mo uthpiece for 
about 30 seconds. See Figure I.
Figure I
Step 11. Shake off as much water from th e actuator as you can. Look into  the mouthpiece to 
make sure any medicine build-up ha s been completely washed away . If there is any build-up, 
repeat Steps 9 and 10. 
Step 12. Let the actuator air-dry overnight. See Figure J.
Confidential and Proprietary Page 105 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Figure J
Step 13. When the actuator is dry, put t he protective cap on the mouthpi ece and then put the 
canister in the actuator and make sure it fits fir mly. Shake th e inhaler well, remove the cap, 
and spray the inhaler once into t he air away from your face. (T he counter will count down by 
1 number.) Put the cap back on the mouthpiece. 
If you need to use your inhaler be fore the actuator is complete ly dry:
â€¢Shake as much water off the actuator as you can.
â€¢Put the cap on the mouthpiece and t hen put the canister in the actuator and make sure 
it fits firmly.
â€¢Shake the inhaler well and spray it 1 time into the air away fr om your face.
â€¢Take your VENTOLIN HFA dose as prescribed. 
â€¢Follow cleaning Steps 8 through 13 above. 
Confidential and Proprietary Page 106 of 112
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Trial Protocol:  PT010008-01 Version 2.0, 
Appendix 6 Investigatorâ€™s Signature 
Study Title: A Randomized, Double-Blind, Par allel-Group, 52-Week, Chronic-
Dosing, Multi-Center Study to A ssess the Safety and Tolerabilit y of 
PT010, PT009 and PT003 in Subjects w ith Moderate to Very Severe  
Chronic Obstructive Pulmonary Disease 
Study Number: PT010008-01
Final Date:
I agree:
â€¢To assume responsibility for the proper conduct of the study at  this site
â€¢To conduct the study in compliance with the protocol and with a ny other study conduct 
procedures provided by Pearl Therapeutics, Inc. (hereafter refe rred to as Pearl)
â€¢Not to implement any changes to the protocol without agreement from Pearl and prior 
review and written approval from the Institutional Review Board /Independent Ethics 
Committee, except where necessary to eliminate an immediate haz ard to the subjects, or 
for administrative aspects of the study (where permitted by all  applicable regulatory 
requirements)
â€¢That I am aware of, and will comply with Good Clinical Practice s and all applicable 
regulatory requirements
â€¢That I am thoroughly familiar with the appropriate use of the i nvestigational product(s), 
and other information provided by Pearl including, but not limi ted to, the following: the 
protocol and the current Investigators Brochure (IB)
â€¢To ensure that all persons assisting me with the study are qual ified, adequately informed 
about the investigational product(s) and of their study-related  duties and functions
â€¢To supply Pearl with any necessary information regarding owners hip interest and financial 
ties; to promptly update this information if any relevant chang es occur during the course of 
the study and for 1 year following completion of the study; and  agree that Pearl may 
disclose any information it has about such ownership interests and financial ties to 
regulatory authorities
â€¢I agree to report all informatio n or data in accordance with th e protocol and any other 
study conduct procedures provided by Pearl
â€¢That since the information in this protocol and IB is confident ial, I understand that its 
disclosure to any third parties, other than those involved in a pproval, supervision, or 
conduct of the study is prohibited
â€¢To accurately transfer all required data from each subjectâ€™s so urce document to the 
electronic case report forms (eCRFs).  The eCRFs will be provid ed to Pearl in a timely 
manner at the completion of the study, or as otherwise specifie d by Pearl
â€¢To allow authorized representatives of Pearl or regulatory auth ority representatives to 
conduct on-site visits to review, audit, and copy study documen ts.  I will personally meet 
with these representatives to answer any study-related question s
Signature:  Date:  
Name:              
Affiliation:                
Confidential and Proprietary Page 112 of 112